

## **CURRICULUM VITAE**

**NAME:** GOLDSTONE

**FORENAMES:** Anthony Howard

**DOB:** 13.09.1944

**SPECIALITY:** Clinical and Laboratory Haematology

### **UNIVERSITY/MEDICAL SCHOOL EDUCATION**

BA Hons. Oxon Physiology	Oxford, June 1965
MA Oxon	Oxford, June 1968
BM BCh Oxon	Oxford, December 1968
MRCP (UK)	October 1971
MRCPath (Haematology)	June 1975
FRCP (Edin)	October 1979
FRCP (London)	1983
FRCPPath	1987

### **CURRENT POST:**

Professor of Haematology  
University College London Hospital and UCLH NHS Trust  
October 1999 - current date

Consultant Haematologist  
University College London Hospital and UCLH NHS Trust  
1976 - current date

Director, North London Cancer Network  
November 2000 - present date

Honorary Contract – Professor of Haematology  
Department of Haematology  
Royal Free NHS Trust  
Pond Street  
Hampstead  
London NW3 2QG

### **PREVIOUSLY**

Clinical Director

Cancer Services and Haematology  
UCLH NHS Trust  
1992 - 2000 (initially Director of Clinical Haematology since September 1977,  
Director of All Cancer Services for the UCH NHS Trust).

Medical Director  
UCLH NHS Trust  
October 1992 - November 2000

**DATE OF MEDICAL REGISTRATION:**

December 1968

**CLINICAL TRAINING AND EXPERIENCE**

House Physician: Medicine  
Chase Farm Hospital, Enfield Feb 1969 - Aug 1969

House Surgeon: Surgery  
Edgware General Hospital Aug 1969 - Feb 1970

Resident Clinical Pathologist  
Guy's Hospital Feb 1970 - Sep 1970

Senior House Officer: Medicine  
University of Edinburgh  
Gastrointestinal Unit  
Western General Infirmary Sep 1970 - Feb 1971

Registrar in Haematology  
Western General Infirmary, Edinburgh Feb 1971 - June 1972

Cancer Research Campaign  
Research Fellow in Clinical Immunology  
Edinburgh Royal Infirmary June 1972 - Oct 1973

Senior Registrar in Haematology  
Addenbrooke's Hospital, Cambridge and  
Department of Haematological Medicine,  
University of Cambridge Oct 1973 - Mar 1976

**TEACHING EXPERIENCE**

Honorary Senior Lecturer  
School of Medicine, Royal Free & University College London

Past Lecturer  
City of London Polytechnic, Paddington College, 1976-1981  
and Addenbrooke's Hospital, Cambridge, 1973-1976

Past Teacher in Pathology  
Churchill College, Cambridge

Girton College, Cambridge  
1973 - 1976

#### **OTHER APPOINTMENTS AND AFFILIATIONS**

1. Fellowship of the Royal College of Physicians of London since 1983 to present.
2. Fellowship of the Royal College of Pathologists 1987 to present.
3. Member of the British Society of Haematology 1975 to present.
4. Chairman Use of Medicines Committee UCLH NHS Trust 1992- present.
5. Medical Director Chairman of Clinical Directors Group UCLH NHS Trust 1992 to present.
6. Co-Chairman of Clinical Governance Group UCLH NHS Trust 1998 to current.
7. Member of Regional High Awards Committee North East Thames 1996 to 1999.
8. Chairman of North East Thames Regional Haematologists 1988 to 1992.
9. Current President of British Society for Blood and Bone Marrow Transplantation December 1998 to December 2000.
10. Vice President Elect British Society for Haematology 1998 (to be President for the year 2001).
11. Editor of Journal Leukaemia and Lymphoma 1993 - 1998 and ongoing.
12. Editorial Review Board Bone Marrow Transplantation for approximately years, 1988 to 1998.
13. Member of Editorial Board of Acta Haematologica 1993 to 1998 and ongoing.

I review papers for the New England Journal of Medicine, Blood, Journal of Clinical Oncology, Annals of Oncology, Bone Marrow Transplantation, British Journal of Haematology, Leukaemia, Leukaemia and Lymphoma. I have been invited to do a book review for the New England Journal of Medicine 1998.

#### **PRIZES AWARDS AND OTHER HONOURS**

Elected Fellow of University College UCL London, 1994.  
A+ Merit Award UK National Health Service, December 1998.

#### **GRANTS RAISED**

1. 1977-1980 3 years Clinical Research Fellowship for the study of plasma exchange in immune disorders. Total: £100,000. Research Fellow, Dr H F Parry. Co-Grant Holder, Professor E R Huehns. From Jules Thorne Foundation.
2. 1981-1982 2 years Clinical Research Fellowship to study platelet activity in diabetes. Total: £40,000. Research Fellow, Dr B A McVerry. From Schering Corporation.
3. 1980-1981 1 year Grant Project 'Automated Cytochemistry in Haematological Malignancy'. Total: £15,000. Research Fellow, Dr K G Patterson. From Technicon Corporation.
4. 1981-1982 2 years Grant Project on 'The Immunology of Ageing'. Total: £40,000. Research Fellow, Mr S McDonald. Co-Grant Holder, Professor A N Exton-Smith.
5. 1983-1984 2 years Grant Project 'The Chemical Use of Young Red Cells'. Total £50,000. Research Fellow, Dr R Marcus. Co-Grant Holder, Professor E R Huehns. From the Medical Research Council.
6. 1984-1985 2 years Grant Project 'The Chemical Use of a Synthetic Prostacyclin in Arterial Disease'. Total: £50,000. Research Fellow, Dr A Yardumian. Co-Grant Holder, Dr S J Machin. From Schering Corporation.
7. 1986-1987 2 years grant 'The Study of Ceftazidime Monotherapy in [Neutropenia]'. Total: £60,000. Research Fellow, Dr S Kinsey. Co-Grant Holder, Dr S J Machin. From Glaxo Ltd.
8. 1987 1 year grant 'T & B Cell typing using the Technicon HI Instrument'. Total: £10,000. Employing one Research Technician. From Technicon Corporation.
9. 1987-1988 2 year Grant 'The Study of Interferon in Myelodysplasia and Myeloma'. Total: £60,000. Research Fellow, Dr F Giles. From Schering Corporation.
10. 1986-1987 2 year Grant 'The Evaluation of Autologous Bone Marrow Transplantation in Haematological Malignancies'. Total: £50,000. Research Fellow, Dr J Gribben. Co-Grant Holders, Professor E R Huehns and D C Linch. From the Leukaemia Research Fund.
11. 1988-1989 2 year Grant 'Ceftazidime vs Ciprofloxacin as Monotherapy in Febrile Neutropenia'. Total: £60,000. Research Fellows, Dr M Smith and Dr S Lim. From Lederle Company.
12. 1987-1990 3 year Grant 'Interferon in CLL, Essential Thrombocythaemia and Myeloma. Total: £300,000. Research Fellow, Dr F Giles. From Roche.
13. 1988-1989 LRF Clinical Fellowship. 2 year salary for ABMT in Lymphoma. Total: £50,000. Research Fellow, Dr A K McMillan.

14. 1990-1991 LRF Clinical Fellowship. 2 year salary for ABMT in Lymphoma. Total: £50,000. Research Fellow, Dr R Chopra.
  15. 1990-1991 2 year Grant 'Meropenem in PUO' Total: £75,000 ICI Research Fellow, Dr H Kelsey with Professor S Machin.
  16. 1991 2 year Grant 'Ondansetron in Emesis with ABMT'. Total: £21,000. From Glaxo.
  17. 1992 2 year grant 'The role of early liposomal amphotericin in neutropenia'. Total: £60,000. From Vestar Corporation.
  18. 1991-1993 LRF Clinical Fellowship. 2 year salary from ABMT in Lymphoma, jointly with Professor D C Linch, Dr W Mills. Total: £60,000.
  19. 1991-1992 1 year grant. 'Interferon in myeloma and hepatitis C. Total: £25,000. Research Fellow, Dr E McSweeney. From Roche Company.
  20. 1992-1998 6 years support Myeloma Research Fellow. 6 x £40,000 = £240,000. From Roche Company.
  21. 1994-1996 Research Fellow for Vancomycin resistant enterococci in haematology patients. Dr Susan Bradley. 2 x £50,000 = £100,000. From Lederle.
  22. 1995-1998 Research Fellow in Fungal Infections. Nexstar Corporation. 3 x £40,000 = £120,000.
- Total: £1,645,000

## **INVITED TALKS**

I have given invited overseas lectures, by invitation, in France, Holland, Spain, Germany, Italy, Sweden, Denmark, Finland, East Germany, Turkey, Israel, Argentina, Australia, Japan, Canada, Switzerland, Belgium, United States of America, Cyprus, Greece, Austria, India, China, Thailand and Ireland. I gave the plenary lecture at the first Indian National Symposium on Autologous Bone Marrow Transplantation in 1991, the plenary lecture at the European Bone Transplantation Group in Cortina in January 1991, the plenary lecture at the International Society of Experimental Haematology in Parma July 1991. I also gave two further plenary lectures at the European Group for Bone Marrow Transplantation. I have also given two educational sessions at the Annual Meeting at the European Group for Bone Marrow Transplantation. I gave the keynote lecture at the New Second National Bone Marrow Transplant Institute in Israel at Tel Hashomer Hospital in Tel Aviv in 1990, reviewing Transplants in Lymphoma in front of the Israeli Minister of Health.

I gave an Education Session on Transplant in Hodgkin's Disease at ASCO (The American Society for Clinical Oncology) meeting in San Diego in 1992.

In 1986 I was invited to the Beijing Union Medical College to give 18 lectures, personally, over 4 days to cover all aspects of autologous bone marrow transplantation to 50 Chinese Haematologists, flown in from all parts of China including Tibet and Outer Mongolia. Each of these lectures was of one hour's duration and was translated line by line by a Chinese interpreter working with me. This involved the preparation of 500 slides for just one visit and the duplication of all of them by the locals to provide teaching material to initiate autologous bone marrow transplantation over the whole of China. ABMT at that time was very important in China since families were restricted to one child per family and any child with acute leukaemia or haematological malignancy could therefore not have a potential sibling as a bone marrow donor. I believe that this series of lectures was the initiating act which began ABMT across many centres in China.

## **ACADEMIC SUPERVISION**

- 1979-1981            Dr H Al-Hadithy  
PhD London University  
'Whole Blood Neutrophil Function Tests'
- 1983-1987            Dr C C Anderson  
MD University of Edinburgh  
'The Use of Autologous Bone Marrow  
Transplantation in Leukaemia and Lymphoma'
- 1989-1990            Dr S H Lim  
MD University of Aberdeen  
'The use of IL-2 in Acute Myeloid Leukaemia'
- 1990-1992            Mr A Jewell  
MSc - PhD University of London  
'The role of interferon in CLL'

## **TEACHING ACTIVITY**

Honorary Senior Lecturer, Royal Free and University College London School of Medicine.

Past lecturer, City of London Polytechnic College and Adenbrooke's Hospital in Haematological Pathology. 1976 - 1981.

Past teacher in Pathology, Churchill College, Cambridge, Gerton College Cambridge. 1973-1976.

## **ENABLING ACTIVITIES**

I have raised, with the Sportsman's Aid Society and other charities the following funds for major building projects and equipment on our Unit.

1. Complete refurbishment of the NHS clinic unit. Cost: £154,000. 1979-1980. Opened by the Queen Mother 1982.
2. The complete refurbishment of the Academic Department of Haematology, UCL, Chenies Mews. Cost: £160,000. Opened by the Queen Mother 1984 and named The Lou Cohen Laboratories.
3. The building of a new laboratory of Inherited Blood Diseases in the Academic Department of Haematology, University College, London, Chenies Mews. 1986. Cost: £60,000. Opened by the then Minister of Health, The Right Honourable Barney Hayhoe, MP.
4. Annexe to the NHS Haematology Ward for teaching in out patient clinics. Cost: £30,000. 1988.

5. The installation of equipment in the Academic Department of Haematology, UCL, 98 Chenies Mews, London WC1. Named the Josephine Francis Laboratory. Cost: £15,000. 1988.

6. Laboratory equipment for the Josephine Francis Laboratory (£54,000), raised by me from the Jackie Woodhouse Memorial Fund. (1990)

7. During the years 1984 to 1987 I was the Postgraduate Dean of the University College Hospital Medical School and was concerned in bringing together the post graduate activities of the former UCH medical school and the former Middlesex Hospital Medical School. During my tenure of office I worked with a group which initiated a series of scientific academic and medical monographs from the joint medical school, known as "The Bloomsbury Series" and edited by Dr Jack Tinker. I was also responsible for the initiation of the joint school MRCP course which later became a major course nationally for both parts one and parts two. I also ran, on a regular basis, post graduate education meetings for general practitioners.

8. I applied for and was successfully interviewed for the post of the first Medical Director for the UCLH NHS Trust in October 1992 and have been the Medical Director ever since. We have integrated into the Trust the Eastman Dental Hospital and the National Hospital for Neurology and Neurosurgery and I am now Medical Director of a complex involving University College Hospital, the Middlesex Hospital, The Elizabeth Garrett Anderson Hospital, the Eastman Dental Hospital, The National Hospital for Neurology and Neurosurgery. We have the second largest R&D income of any NHS Trust in the United Kingdom.

9. I have worked with the European Group for Blood and Bone Marrow Transplantation (EBMT) for many years. I saw the opportunity and necessity for a lymphoma registry, founded it and nursed it all together over 14 years. My recent contribution to the EBMT has been to persuade the Board to transform the organisation from a registry based one to a prospective trials organisation. I submitted a proposal to the EBMT to centralise the majority of the disparate data management collection. in Europe in the London Office of University College London, which is part of the new UCLH/CRC Trials Centre, encompassing the CRC trials office which has moved to UCL from Kings College, London, along with the Lung Cancer Group, The British National Lymphoma investigation and now the major office of the European Group for Bone Marrow Transplantation. The EBMT has become an important part of this quadripartite organisation.

## **RESEARCH ACTIVITIES**

I have published extensively since my early days in haematology. My major academic contribution has been in the exploration of dose escalation of patients in adult leukaemia, lymphoma and myeloma in remission and relapse. Over the past 15 years Professor David Linch at UCL and myself are members of a small group of individuals who have brought the technique of dose escalation with stem cell rescue, first by bone marrow transplantation and later by stem cell transplantation towards standard therapy for relapsed patients with leukaemia and lymphoma. Working with the UK Medical Research Council, and particularly Professor Alan Burnett. I have

contributed to revolutionise the approach to randomised trials in adult leukaemia in the UK, in both acute myeloid leukaemia and acute lymphoblastic leukaemia. These trials are recognised in being in the fore front of the international contribution in clinical trials for leukaemia. The MRC AML 10 trial, which we published jointly (Professor Burnett and myself) was originally devised by the two of us as the largest randomised clinical trial looking at the role of autologous allogeneic bone marrow transplantation in adult acute myeloid leukaemia. Almost every single hospital, of any size, in the UK is now a collaborator in the MRC AML Adult Leukaemia Trials.

I have been associated with devising clinical trials for the Medical Research Council in Leukaemia for over 10 years, including major roles in AML 10, a randomised trial of autologous bone marrow transplantation - v - no further consolidation therapy in adults in acute leukaemia remission. I have also been involved in devising AML 11, the largest single trial of chemotherapy in the elderly, looking at truncated - v - extended therapy in acute myeloid leukaemia and looking at 3 different induction regimens plus the role of maintenance Interferon.

I have been involved in the design and implementation of the two successors to these trials, AML12 and AML14 respectively. I am also the deviser and major co-ordinator of the current adult acute lymphoblastic leukaemia trial, UKALL 12, which is a prospective randomised study testing autologous bone marrow transplantation - v - conventional chemotherapy in patients who have no matched sibling donor.

I was personally responsible for the liaison with the Eastern Co-operative Oncology Group (ECOG) of the United States, which has resulted in the first major collaborative study in acute leukaemia between the MRC and a major United States collaborative group (UKALL 12/ECOG 2993).

With the European Group for Bone Marrow Transplantation I was amongst a very small group who first impressed upon that organisation the emerging importance of autologous bone marrow transplantation and the role of that technology in non-Hodgkin's lymphoma and Hodgkin's disease in particular. I saw the opportunity and necessity for a lymphoma registry and founded it and nursed it and grew it for altogether over 14 years. During that time I was Chairman of the Lymphoma Group of the EBMT and for the last 6 years until 1998 was a member of the board.

I have organised and supervised the collection of data now on over 17,000 patients who have had transplants with lymphoma and have initiated directed or supported five prospective randomised trials for the EBMT Lymphoma Group, one of which has already been completed and presented as an oral presentation at the American Society for Clinical Oncology (ASCO) in 1998.

Working with Professor Linch we devised and implemented, the first and so far only prospective randomised trial of ABMT in Hodgkin's disease and initiated, with European collaborators, the only prospective randomised trial of autologous bone marrow transplantation - v - autologous peripheral blood transplantation in relapsed patients with lymphoma. Subsequently, Professor Linch and myself have become the major referral centre for dose escalation in relapsed lymphoma in the UK, one of a

few major European centres and would be ranked within the top 3 or 4 in the world for patients needing such therapy.

I have also developed an interest in dose escalation in myeloma, I have started a transplant programme which is now one of the largest in the UK and have carried out a total of over 100 high dose procedures in myeloma with autologous marrow, autologous peripheral blood stems cells, CD34 selective stems cells and allogeneic transplants.

I have frequently been an invited speaker when dose escalation in haematological malignancy is discussed at national and international meetings.

My major contribution to research has thus been along the theme of dose escalation with stem cell rescue in leukaemia and lymphoma and the implementation of large randomised clinical trials to test the hypothesis generated by the preliminary data. Also I have devised, constructed and operated a lymphoma transplant registry of over 17,000 patients.

## **PUBLICATIONS**

### **A. Books**

- A1** 1. Goldstone AH, Cawley JC, Hayhoe FGJ. 1976.  
Leukaemia, Lymphoma and Allied Disorders.  
WB Saunders & Co., London, Phil., Toronto. 314 pp
2. Goldstone AH. 1977.  
Examination Haematology.  
WB Saunders & Co. 206 pp.
3. Richards JDM, Linch DC, Goldstone AH. 1983.  
Synopsis of Haematology. John Wright. Bristol. 306 pp.

### **Edited (Co-Edited) Books**

- A2** 4. Goldstone AH. (Ed). 1986.  
Clinics in Haematology: Autologous Bone Marrow Transplantation.  
WB Saunders & Co.

### **Chapters**

- A3** 5. Goldstone AH 1973.  
Immunological Aspects of Blood Disease.  
In: Medical Immunology. Ed. WJ Irvine. Teviot press.
6. Singer CRJ, Goldstone AH. 1985.  
Recent Advances in Blood Transfusion and Blood Products.  
In: Recent Advances in Anaesthesia (I). Ed: L Kaufman.
7. Singer CRJ, Goldstone AH. 1985.  
Autologous Bone Marrow Transplantation in non-Hodgkin's lymphoma. I  
n: Clinics in Haematology: ABMT. Ed: AH Goldstone.
8. Singer CRJ, Goldstone AH.  
Clinical studies of ABMT in non-Hodgkin's lymphoma.  
Clinics in Haematology 15:105-150. 1986.
9. Goldstone AH, Gribben JG, Singer CRJ. 1987.  
Haematology.  
In: Medicine for Anaesthetists. Ed: J. Betteridge.
10. Goldstone AH, Singer CRJ. 1991.  
The Chronic Leukaemias.  
In: The Oxford Textbook of Oncology.
11. Singer CRJ, Goldstone AH.  
The Chronic Leukaemias.  
In: Oxford Textbook of Oncology 1995.

12. McMillan AN, Goldstone AH, Chopra R.  
In: High Dose Chemotherapy.  
Ed. Armitage & Antran. 1995.  
Publishers Williams & Williams.

13. Linch DC, Goldstone AH, Mason DY.  
The Lymphomas.  
In: Postgraduate Haematology.  
Ed: Hoffbrand AV. 1998.

13: Durrant IJ, Richards SM, Prentice HG, Goldstone AH.  
The Medical Research Council trials in adult acute lymphocytic leukemia.  
Hematol Oncol Clin North Am. 2000 Dec;14(6):1327-52. Review.

## **B. REFEREED ARTICLES**

1. Wood JK, Goldstone AH, Allen NC. 1972.  
Folic Acid and The Pill.  
Scand. J. Haem 9: 539-544

2. Goldstone AH, Calder EA, Barnes EW, Irvine WJ. 1973  
Delayed hypersensitivity in gastric antigens in pernicious anaemia and  
atrophic gastritis.  
Clin. Exp. Immun. 14: 501-508

3. Goldstone AH, Wood JK, Cook M. 1973  
Myeloma in mother and daughter.  
Acta Haematologica 49: 176-181.

4. Goldstone AH, Kerr L, Irvine WJ. 1973  
The macrophage electrophoretic migration test in cancer.  
Clin. Exp. Immun. 14:469-472

5. McCuish AC, Urbaniak SJ, Goldstone AH, Irvine WJ. 1974.  
PHA responsiveness and subpopulations of circulating lymphocytes in  
pernicious anaemia.  
Blood, 44:849-855

6. Cawley JC, Goldstone AH, Arno J, Grant A. 1974.  
Myeloma in a case of Hodgkin's disease.  
Acta haematologica, 42:349-355

7. Haegert DG, Cawley JC, Karpas A, Goldstone AH. 1974  
Combined T & B cell acute lymphoblastic leukaemia.  
Brit. Med. J. 4:79-82

8. Cawley JC, Emmines J, Goldstone AH, Hamblin T, Hough T, Smith JL. 1975.  
Distinctive cytoplasmic inclusions in chronic lymphocytic leukaemia.  
European J. Cancer, 11:91-92
9. Goldstone AH, Urbaniak SJ, Irvine WJ. 1975.  
Electrophoresis of lymphocytes from normal human subjects and patients with chronic lymphocytic leukaemia.  
Clin. and Exp. Immunol. 17:113-120
10. Cawley JC, Goldstone AH, Smith JL, Hamblin T, Hough D. 1976.  
IgA and IgM cytoplasmic inclusions of immunoglobulins in a series of cases of CLL.  
Clin. and Exp. Immunol. 23:78-82
11. Goldstone AH, Voak D, Cawley JC, Irvine WJ. 1976.  
HLA antigens in pernicious anaemia.  
Clin. and Exp. Immunol. 25:352-354.
12. Goldstone AH, Cawley JC, Barker CR, Roberts SO, Levantine A. 1976.  
A case of small cell Sezary syndrome with null cell features.  
J Clin. Path. 29:848-851
13. Burns GF, Cawley JC, Barker CR, Goldstone AH, Hayhoe FGJ. 1977.  
New evidence relating to the nature and origin of the hairy cell of LRE.  
Brit. J. Haem. 36:71-84
14. Janossy G, Goldstone AH, Capellaro D, Greaves MF, Kelenhamff J, Pippard M, Kay H, Welsh K. 1977.  
Differentiation linked loss of Ia-like structures on human leukaemic cells.  
Brit J Haem. 37:391-402
15. Burns GF, Cawley JC, Worman CP, Karpas A, Barker CR, Goldstone AH, Hayhoe FGJ. 1978  
Multiple heavy-chain isotypes on the surface of the cells of hairy cell leukaemia.  
Blood 52:1132-1147
16. Janossy G, Francis G, Greaves MF, Capellaro D, Goldstone AH. 1978  
Cell sorter analysis of leukaemia - associated antigens on human myeloid precursors.  
Nature. 1978. 276 (568) 176-8
17. Goldstone AH, McVerry BA, Janossy G, Walker H. 1979.  
Clonal identification in acute leukaemia.  
Blood 53:892-898
18. Al-Hadithy H, Addison IE, Goldstone AH. 1980.  
The use of whole blood in the measurement of neutrophil migration.

J Clin. Path. 34:158-162

19. McVerry BA, Goldstone AH, Janossy G. 1980.  
Acute promyelocytic leukaemia - an Ia negative acute leukaemia. Further evidence of differentiation linkage of the Ia antigen.  
Scand. J. Haem. 22:53-56
20. Patterson KG, Cawley JC, Richards JDM, Janossy G, Goldstone AH. 1980.  
A comparison of automated cytochemical analysis and conventional methods in the classification of acute leukaemias.  
Clin. Lab. Haematology. 2:281-291.
21. McVerry BA, Machin S, Parry HF, Goldstone AH. 1980.  
Reduced prostacyclin activity in SLE.  
Annals of Rheumatic Disease. 40:224-225
22. Segal AW, Garcia R, Goldstone AH. 1981.  
Cytochrome b-245 of neutrophils is also present in human monocytes, macrophages and eosinophils.  
Biochem. J. 196:363-367.
23. Patterson KG, Goldstone AH, Richards JDM, Cawley JC.  
A Haemalog-D analysis of chronic lymphocytic leukaemia and other lymphoproliferative disorders affecting the blood.  
Journal of Clinical Pathology. 34:473-478, 1981.
24. Oladimeji M, Grimshaw AD, Baum M, Patterson KG, Goldstone AH.  
Effect of surgery on monocyte function.  
British Journal of Surgery 69: 145-146. 1982.
25. Patterson KG, Goldstone AH, Richards JDM, Cawley JC.  
Increased neutrophil peroxidase-activity in acute myeloid leukaemia.  
Acta Haematologica 68:261-267. 1982.
26. Souhami RL, Harper PG, Linch D, Trask C, Goldstone AH, Tobias J, Spiro SG, Geddes DM, Richards JDM.  
High dose cyclophosphamide with autologous marrow transplantation as initial treatment of small cell carcinoma of the bronchus.  
Cancer chemotherapy and pharmacology 8:31-34, 1982.
27. Worman CP, Mills KHG, Linch DC, Beverley PCL, Goldstone AH, Cawley JC.  
Amegakaryocytic thrombocytopenia associated with an excess of leu 2a& suppressor cells.  
Scandinavian Journal of Haematology 28:215-219. 1982.
28. Alhadithy H, Addison IE, Goldstone AH.  
Use of whole blood in the measurement of neutrophil migration.

- Journal of Clinical Pathology 33:158-162, 1982.
29. Alhadithy HA, Addison IE, Goldstone AH.  
A rapid whole blood technique for assessment of neutrophil phagocytosis and killing.  
Clinical and Laboratory Haematology 3:85-88. 1982.
30. Harper PG, Linch DC, Goldstone AH, Richards JDM, Souhami RL.  
Haematological effects of high dose cyclophosphamide and autologous bone marrow transplantation.  
British Journal of Haematology 49:138-139. 1982.
31. Parry HF, Moran CJ, Snaith ML, Richards JDM, Goldstone AH, Nineham LJ, Hay FC, Morrow WJW, Roitt IM.  
Plasma exchange in systemic lupus erythematosus.  
Annals of the rheumatic diseases. 40:224-228. 1982.
32. Hughes A, McVerry BA, Wilkinson L, Goldstone AH, Lewis D, Blood A.  
Diabetes, a hypercoagulable state - haemostatic variables in newly diagnosed type-2 diabetic patients.  
Acta Haematologica 69:254-259. 1983.
33. Levinsky RJ, Davies EG, Butler M, Linch DC, Goldstone AH.  
Problems of mismatched bone marrow transplantation for severe combined immunodeficiency using soy bean lectin fractionation.  
Experimental haematology. 11:89-90. 1983.
34. Linch DC, Knott LJ, Thomas RM, Harper P, Goldstone AH, Davis EG, Levinski RJ.  
T Cell regeneration after allogeneic and autologous bone marrow transplantation.  
British Journal of Haematology 53:451-458. 1983.
35. Souhami RL, Harper PG, Linch D, Trask C, Goldstone AH, Tobias JS, Spiro SG, Geddes DM, Richards JDM.  
High dose cyclophosphamide with autologous marrow transplantation for small cell carcinoma of the bronchus.  
Cancer Chemotherapy and Pharmacology 10:205-207. 1983.
36. Alhadithy H, Cawley JC, Addison IE, Gandossini M, Souhami RL, Goldstone AH.  
Neutrophil function in advanced Hodgkin's disease - effect of therapy.  
Leukaemia Research. 6:261-267. 1983.
37. Alhadithy H, Isenberg DA, Addison IE, Goldstone AH, Snaith ML.  
Neutrophil function in systemic lupus erythematosus and other collagen diseases.  
Annals of the Rheumatic Diseases. 41:33-38. 1983.

38. Asker RL, Renwick JH, Goldstone AH.  
Erythrocyte volume as a crude indicator of ethanol-consumption in pregnancy.  
*Clinical and Laboratory Haematology* 4:326-329. 1983.
39. Isenberg DA, Patterson KG, Toddpokropek A, Snaith ML, Goldstone AH.  
Haematological aspects of systemic lupus erythematosus - a reappraisal using  
automated methods.  
*Acta Haematologica* 67:242-248. 1982.
40. Levinsky RJ, Davies EG, Linch D, Goldstone AH, Beverley PCL.  
Soy bean lectin fractionation of bone marrow to prevent graft versus host  
disease (GVH) in mismatched transplants.  
*Experimental Haematology*. 10:96-98. 1982.
41. Linch DC, Walker H, Roberts P, Mckinnon J, Goldstone AH, Huehns ER.  
A chronic myeloproliferative disorder associated with monosomy-7 in the  
bone marrow cells - normal kayotype in acute transformation.  
*British Journal of Haematology*. 51:439-444. 1982.
42. Macdonald SM, Goldstone AH, Morris JE, Extonsmith AN, Callard RE.  
Immunological parameters in the aged and Alzheimer's disease.  
*Clinical and Experimental Immunology*. 49:123-128. 1982.
43. Marcus RE, Thomas MJG, Parry ES, Cowan D, Goldstone AH, Huehns  
ER.  
Young red cell preparation - a comparison of available methods.  
*Acta Haematologica* 73:22-25. 1985.
44. Philip T, Biron P, Maraninchi D, Goldstone AH, Herve P, Souillet G,  
Gastaut JL, Plouvier E, Flesh Y, Philip I, Harousseau JL, Lemevel A, Rebattu  
P, Linch DC, Freycon F, Milan JJ, Souhami RL.  
Massive chemotherapy with an autologous bone marrow transplantation in 50  
cases of bad prognosis non Hodgkin's lymphoma.  
*British Journal of Haematology*. 60:599-609. 1985.
45. Singer CRJ, Walker H, Patterson J, Goldstone AH, Prentice HG,  
Mixed haematopoietic chimaerism after BMT detected by sex chromosome  
analysis - correlation with clinical outcome.  
*British Journal of Haematology*. 61:561-562. 1985.
46. Souhami RL, Finn G, Gregory WM, Birkhead BG, Buckman R, Edwards  
D, Goldstone AH, Harper PG, Spiro SG, Tobias JS, Geddes D.  
High dose cyclophosphamide in small cell carcinoma of the lung.  
*Journal of Clinical Oncology* 3:958-963. 1985.
47. Yardumian DA, Mackie KJ, Bull H, Goldstone AH, Machine SJ.  
Platelet hyperaggregability occurring during prolonged continuous  
intravenous infusions of prostacyclin analogue zk-36374.

- British Journal of Haematology. 60:109-116. 1985.
48. Anderson CC, Linch DC, Jones M, Closs SP, Cawley JC, Richards JDN, Goldstone AH.  
Autologous bone marrow transplantation for patients with acute leukaemia who are not candidates for allogeneic transplantation.  
British Journal of Haematology 58:196-197. 1985.
49. Jones HM, Linch DC, Marcus RE, Singer CR, Goldstone AH.  
Red cell removal from donor bone marrow.  
British Journal of Haematology. 58:553-554. 1985.
50. Goldstone AH, Harper PG, Linch DC, Souhami RL, Anderson CC, Moss FM, Martin PJ, Richards JDM.  
Patterns of haematological recovery in autologous bone marrow transplantation for small cell carcinoma of bronchus, carcinoma of the ovary and acute leukaemia and lymphoma.  
Experimental Haematology. 11:164-167. 1985.
51. Goldstone AH, Anderson CC, Linch DC, Franklin IM, Boughton BJ, Cawley JC, Richards JDM.  
Autologous bone marrow transplantation following high dose chemotherapy for the treatment of adult patients with acute myeloid leukaemia.  
British Journal of Haematology. 64:529-537. 1986.
52. Isenberg DA, Martin P, Hajirousou Vi, Toddpokropek A, Goldstone AH, Snaith ML.  
Haematological reassessment of rheumatoid arthritis using an automated method.  
British Journal of Rheumatology. 25:152-157. 1986.
53. Lai AP, Martin PJ, Richards JDM, Goldstone AH, Cawley JC.  
Automated leukocyte differential counts in acute leukaemia - a comparison of the hemalog-D, h6000 and Coulter S+4.  
Clinical and laboratory Haematology. 8:33-41. 1986.
54. Martin PJ, Anderson CC, Jones HM, Lai AP, Linch DC, Goldstone AH.  
A rise in the percentage of large unstained cells in the peripheral blood determined by the Haemalog-D 90 automated differential counter is a feature of impending myeloid engraftment following bone marrow transplantation.  
Clinical and Laboratory Haematology. 8:1-8. 1986.
55. Walker H, Singer CRJ, Patterson J, Goldstone AH, Prentice HG.  
The significance of host hematopoietic cells detected by cytogenetic analysis of bone marrow from recipients of bone marrow transplants.  
British Journal of Haematology. 62:385-391. 1986.
56. Anderson CC, Souhami RL, Linch DC, Cawley JC, Harper PJ, Machin SJ, Jelliffe AM, Richards JDM, Goldstone AH.

Local experience in treating advanced lymphoma with intensive chemotherapy followed by autologous bone marrow rescue.  
British Journal of Haematology. . 61:563-564. 1986.

57. Lai AP, Martin PJ, Cawley JC, Richards JDM, Goldstone AH.  
Automated leukocyte differential counts in chronic lymphocytic and hairy cell leukaemias - a comparison of the hemalog-D, H6000 and Coulter s+4.  
Clinical and laboratory haematology. 9:169-174. 1987.

58. Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY, Colmbat P, Goldstone AH, Gorin NC, Flesh M, Laporte JP, Maraninchi D, Pico J, Bosly A, Anderson C, Schots R, Biron P, Cabanillas F, Dicke K.  
High dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate grade or high grade non Hodgkin's lymphoma.  
New England Journal of Medicine. 316:1493-1498, 1987.

59. Singer CRJ, Bown SG, Linch DC, Huehns ER, Goldstone AH.  
Phthalocyanine photosensitization for invitro elimination of residual acute non lymphoblastic leukaemia - preliminary evaluation.  
Photochemistry and Photobiology. 46:745-749. 1987.

60. Webster A, Russell SJ, Souhami RL, Richards JDM, Goldstone AH, Gruneberg RN.  
Use of Teicoplanin for Hickman catheter associated staphylococcal infection in immunosuppressed patients.  
Journal of Hospital Infection. 10:77-82. 1987.

61. Anderson CC, Goldstone AH, Souhami RL, Linch DC, Harper PG, McLennan KA, Jones M, Machin SJ, Jelliffe AM, Cawley JC, Richards JDM.  
Very high dose chemotherapy with autologous bone marrow rescue in adult patients with resistant relapsed lymphoma.  
Cancer Chemotherapy and Pharmacology. 16:170-175. 1987.

62. Armitage RJ, Goldstone AH, Richards JDM, Cawley JC.  
Lymphocyte function after autologous bone marrow transplantation (BMT) - A comparison with patients treated with allogeneic BMT and with chemotherapy only.  
British Journal of Haematology. 63:637-647. 1986.

63. Giles FJ, Newland AC, Goldstone AH.  
Therapy of immune mediated thrombocytopenia post autologous bone marrow transplantation - a pilot study.  
British Journal of Cancer. 58:545. 1988.

64. Kinsey SE, Carter AB, Watts MJ, Goldstone AH, Machine SJ.  
The use of H1 in predicting marrow recovery following ablative chemotherapy in leukaemia and lymphoma.  
Clinical and Laboratory Haematology. 10:1-5. 1988.

65. Russell SJ, Walker H, Giles FJ, Goldstone AH.  
Ring chromosome-6 and i(17q-) in a patient with acute promyelocytic leukaemia - absence of translocation t(15-17).  
*Cancer Genetics and Cytogenetics* 34:273-276. 1988.
66. Singer CRJ, Linch DC, Bown SG, Huehns ER, Goldstone AH.  
Differential phthalocyanine photo sensitisation of acute myeloblastic leukaemia progenitor cells - a potential purging technique for autologous bone marrow transplantation.  
*British Journal of Haematology*. 68:417-422. 1988.
67. Anderson CC, Goldstone AH, Linch DC, Jones HM, Franklin IM, Boughton BJ, Cawley JC, Richards JDM.  
Autologous bone marrow transplantation for patients with acute myeloid leukaemia and acute lymphoblastic leukaemia - a comparison.  
*Bone Marrow Transplantation*. 1:271-279. 1988.
68. Vyas P, Kinsey SE, Goldstone AH.  
Scabies infestation following autologous bone marrow transplantation.  
*Leukaemia and Lymphoma*. 3:73-74. 1989.
69. Addison IE, Johnson B, Devereux S, Goldstone AH, Linch DC.  
Granulocyte macrophage colony stimulating factor may inhibit neutrophil migration *in vivo*.  
*Clinical and Experimental Immunology*. 76:149-153. 1989.
70. Devereux S, Linch DC, Gribben JG, Mcmillan A, Patterson K, Goldstone AH.  
GM-CSF accelerates neutrophil recovery after autologous bone marrow transplantation for Hodgkin's disease.  
*Bone Marrow Transplantation*. 4:49-54. 1989.
71. Gribben JG, Goldstone AH, Linch DC, Taghipour G, Mcmillan AK, Souhami RL, Earl H, Richards JDM.  
Effectiveness of high dose combination chemotherapy and autologous bone marrow transplantation for patients with non Hodgkin's lymphomas who are still responsive to conventional dose therapy.  
*Journal of Clinical Oncology*. 7:1621-1629. 1989.
72. Gribben JG, Goldstone AH, Linch DC, Macmillan AK, Richards JDM.  
Double autologous bone marrow transplantation in acute myeloid leukaemia.  
*Bone marrow transplantation*. 4:209-211. 1989.
73. Gribben JG, Linch DC, Singer CRJ, Mcmillan, AK, Jarrett M, Goldstone AH.  
Successful treatment of refractory Hodgkin's disease by high dose combination chemotherapy and autologous bone marrow transplantation.  
*Blood* 73:340-344. 1989.

74. Souhami RL, Hajichristou HT, Miles DW, Earl HM, Harper PG, Ash CM, Goldstone AH, Spiro SG, Geddes DM, Tobias JS.  
Intensive chemotherapy with autologous bone marrow transplantation for small cell lung cancer.  
*Cancer Chemotherapy and Pharmacology*. 24:321-325. 1989.
75. Wagner L, Goldstone AH, Worman CP.  
Demonstration of the increase in serine esterase-positive T-cells in hairy cell leukaemia patients undergoing alpha-interferon therapy.  
*Leukaemia* 3:373-379. 1989.
76. Demel WCP, Hoffbrand AV, Giles FJ, Goldstone AH, Mehta AB, Ganeshaguru K.  
Alpha Interferon therapy for haematological malignancies - correlation between in vivo induction of the 2',5' oligoadenylate system and clinical response.  
*British Journal of Haematology*. 74:452-456. 1990.
77. Giles FJ, Anderson CC, Grant IR, Hoffbrand AV, Mehta AB, Machin SJ, Goldstone AH.  
Recombinant alpha-2a interferon - an effective maintenance agent in essential thrombocythaemia.  
*Leukaemia and Lymphoma*. 3:102-107. 1990.
78. Giles FJ, Smith MP, Goldstone AH. Chlorambucil lung toxicity.  
*Acta Haematologica*. 83:156-158. 1990.
79. Gorin NC, Aegerter P, Auvert B, Meloni G, Goldstone AH, Burnett A, Carella A, Korbling M, Herve P, Maraninchi D, Lowenberg R, Verdonck LF, Deplanque M, Hermans J, Helbig W, Porcellini A, Rizzoli V, Alesandrino EP, Franklin IM, Reiffers J, Collesell P, Goldman JM.  
Autologous bone marrow transplantation for acute myelocytic leukaemia in first remission - a European survey of the role of marrow purging.  
*Blood* 75:1606-1614. 1990.
80. Gribben JG, Devereux S, Thomas MSB, Keim M, Jones HM, Goldstone AH, Linch DC.  
Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF.  
*Lancet* 335:434-437. 1990.
81. Kinsey SE, Machin SJ, Goldstone AH.  
Ceftazidime monotherapy is as effective as Ceftazidime combined with gentamicin in the treatment of febrile neutropenic patients.  
*Journal of Hospital Infections*. 15:49-53. 1990.
82. Lim SH, Smith MP, Goldstone AH, Machin SJ.

A randomised prospective study of Ceftazidime and ciprofloxacin with or without teicoplanin as an empiric antibiotic regimen for febrile neutropenic patients.

British Journal of Haematology. 76:41-44. 1990.

83. Lim SH, Smith MP, Machin SJ, Goldstone AH.

Prophylactic Teicoplanin during insertion of Hickman catheters.

British Journal of Haematology. 76:27-29. 1990.

84. McMillan AK, Goldstone AH, Linch DC, Gribben JG, Patterson KG, Richards JDM, Franklin I, Boughton BJ, Milligan DW, Leyland M, Hutchison RM, Newland AC.

High dose chemotherapy and autologous bone marrow transplantation in acute myeloid leukaemia.

Blood 76:480-488. 1990.

85. Lim SH, Worman CP, Jewell AP, Goldstone AH.

Cellular cytotoxic function and potential in acute myelogenous leukaemia.

Leukaemia Research. 15:641-644. 1991.

86. Lim SH, Worman CP, Callaghan T, Jewell A, Smith MP, Goldstone AH.

Continuous intravenous infusion of high dose recombinant interleukin-2 for advanced lymphomas - a phase-II study.

Leukaemia Research. 15:435-440. 1991.

87. Lim SH, Mcmillan MK, Chopra RAJ, Kinsey SE, Cervi P, Salooja N, Smith MP, Holton J, Linch DC, Goldstone AH.

Transplant related septicaemia in patients undergoing autologous bone marrow transplantation for lymphoma and acute leukaemia.

Leukaemia and Lymphoma. 5:127-132. 1991.

88. Lim SH, Mcmillan AK, Gribben J, Galvin MC, Goldstone AH.

A unique case of 3 autografts for acute myelogenous leukaemia with subsequent long term survival in 2nd remission.

Leukaemia and Lymphoma 5:207-209. 1991.

89. Lim SH, Worman CP, Goldstone AH.

Lymphocyte activation in patients with acute myeloid leukaemia evidence for the presence of myeloblast antigen.

Cancer Immunology Immunotherapy. 33:417-420. 1991.

90. Lim SH, Giles FJ, Smith MP, Goldstone AH.

Bacterial infections in lymphoma patients treated with recombinant interleukin-2.

Acta Haematologica 85:135-138. 1991.

91. Lim SH, Worman CP, Jewell A, Goldstone AH.

Production of tumour derived suppressor factor in patients with acute myeloid leukaemia.

- Leukaemia Research. 15:263-268. 1991.
92. Lim SH, Callaghan T, Goldstone AH.  
Thyroid disorders in 2 cases of acute myeloid leukaemia following treatment with recombinant interleukin-2 infusion.  
Acta Haematologica 85:49-50. 1991.
93. Lim SH, Smith MP, Salooja N, Machin SJ, Goldstone AH.  
A prospective randomised study of prophylactic teicoplanin to prevent early Hickman catheter-related sepsis in patients receiving intensive chemotherapy for haematological malignancies.  
Journal of Anti microbial Chemotherapy. 28:109-116. 1991.
94. Turner-Stokes L, Jones D, Patterson KG, Todd-Pokropell A, Isenberg DA, Goldstone AH.  
Measurement of haematological indexes of chronic rheumatic disease with 2 newer generation automated systems, the H1 and H6000 (technicon).  
Annals of Rheumatic Diseases. 50:583-587. 1991.
95. Khwaja A, Linch DC, Goldstone AH, Chopra R, Marcus RE, Wimperis J Z, Russell NH, Haynes AP, Milligan DW, Leyland MJ, Winfield DA, Hancock BW, Newland A, Durrant ST, Devereux S, Roitt S, Collins M, Hudson GV.  
Recombinant human granulocyte macrophage colon stimulating factor after autologous bone marrow transplantation for malignant lymphoma - a British National Lymphoma Investigation double-blind, placebo controlled trial.  
British Journal of Haematology. . 82:317-323. 1992.
96. Lim SH, Smith MP, Machin SJ, Goldstone AH.  
Teicoplanin and prophylaxis of Hickman catheter insertions.  
European Journal of Surgery: 39-42. 1992.
97. Lim SH, Newland AC, Kelsey S, Bell A, Offerman E, Rist C, Gozzard D, Bareford D, Smith MP, Goldstone AH.  
Continuous intravenous infusion of high dose recombinant interleukin - 2 for acute myeloid leukaemia - a phase-II study.  
Cancer immunology Immunotherapy. 34:337-342. 1992.
98. Tsakona CP, Kinsey SE, Goldstone AH.  
Use of flow cytochemistry via the H1 in FAB identification of acute leukaemias.  
Acta Haematologica. 88:72-77. 1992.
99. Tsakona CP, Goldstone AH.  
Use of flow cytochemistry in early diagnosis of acute myocardial infarction.  
Clinical and Laboratory Haematology. 14:338-340. 1992.
100. Tsakona CP, Khwaja A, Goldstone AH.

Growth factor administration in lymphoma transplants - use of flow cytochemistry via the H-1 in predicting engraftment.  
Leukaemia and Lymphoma. 6:369-375. 1992.

101. Tsakona CP, Goldstone AH.  
Patterns of preliminary degranulation as indicated by the mean myeloperoxidase index (MPXI) during bacteraemia in lymphoma transplants treated with growth factors.  
Clinical and Laboratory Haematology. 14:273-280. 1992.

102. Chopra R, Blair S, Strang J, Cervi P, Patterson KG, Goldstone AH.  
Liposomal amphotericin-b (ambisome) in the treatment of fungal infections in neutropenic patients.  
Journal of Antimicrobial Chemotherapy. 28:93-104. 1992.

103. Chopra R, Goldstone AH, Mcmillan AK, Powles R, Smith AG, Prentice HG, Reid C, Marcus R, Bell A, Milligan D, McCarthy DG, Barnard D.  
Successful treatment of acute myeloid-leukaemia beyond 1st remission with autologous bone marrow transplantation using cyclophosphamide and unpurged marrow - the British Autograft Group experience.  
Journal of Clinical Oncology. 9\_1840-1847. 1991.

104. Giles FJ, Worman CP, Jewell AP, Goldstone AH.  
Recombinant alpha-interferons, thyroid irradiation and thyroid disease.  
Acta Haematologica. 85:160-163. 1992.

105. Williams CD, Goldstone AH, Pearce R, Green S, Armitage JO, Carella A, Meloni G.  
Autologous bone marrow transplantation for paediatric Hodgkin's disease - a case matched comparison with adult patients by the European Bone Marrow Transplant group lymphoma registry.  
Journal of Clinical Oncology. 11:2243-2249. 1992.

106. Chopra R, Linch DC, Mcmillan AK, Blair S, Patterson KG, Moir D, Richards JDM, Cervi P, Kinsey S, Goldstone AH.  
Mini beam followed by beam and ABMT for very poor risk Hodgkin's disease.  
British Journal of Haematology. 81:197-202, 1992.

107. Chopra R, Goldstone AH, Pearce R, Philip T, Petersen F, Appelbaum F, Devo E, Ernst P.  
Autologous versus allogeneic bone marrow transplantation for non Hodgkin's lymphoma - a case controlled analysis of the European bone marrow transplant group registry data.  
Journal of Clinical Oncology. 10:1690-1695. 1992

108. Chopra R, Fielding A, Goldstone AH.

Successful treatment of fungal infections in neutropenic patients with liposomal amphotericin (ambisome) - a report on 40 cases from a single centre.

Leukaemia and Lymphoma. 7:73-77, 1992.

109. Giles FJ, Mcsweeney EN, Richards JDM, Tobias JS, Gaminara EJ, Grant IR, Kearney JW, Newland AC, Parker NE, Schey S, Goldstone AH.

Prospective randomised study of double hemibody irradiation with and without subsequent maintenance recombinant alpha-2b interferon on survival in patients with relapsed multiple-myeloma.

European Journal of Cancer. 28A:1392-1395. 1992.

110. Jewell AP, Worman CP, Giles FJ, Goldstone AH, Lydyard PM.

Resistance of chronic lymphocytic leukaemia cells to interferon alpha generated lymphokine activated killer cells.

Leukaemia and Lymphoma. 7:473-480. 1992.

111. Jewell AP, Yong KL, Worman CP, Giles FJ, Goldstone AH, Lydyard PM.

Cytokine induction of leukocyte adhesion molecule-1 (Iam-1) expression on chronic lymphocytic leukaemia cells.

Leukaemia 6:400-404. 1992.

112. Khwaja A, Yong K, Jones HM, Chopra R, Mcmillan AK, Goldstone AH, Patterson KG, Matheson C, Ruthven K, Abramson SB, Linch DC.

The effect of macrophage colony stimulating factor on haematopoietic recovery after autologous bone marrow transplantation.

British Journal of Haematology. 81:288-295. 1992.

113. McSweeny EN, Giles FJ, Worman CP, Jewel AP, Tsakon CP, Hoffbrand AV, Mehta AB, Newland AC, Cawley JC, Galvani D, Singer CRJ, Grant IR, Norfolk DR, Goldstone AH.

Recombinant interferon alfa 2 a in the treatment of patients with early stage-B chronic lymphocytic leukaemia.

British Journal of Haematology. 85:77-83. 1993.

114. Mcsweeney EN, Worman CP, Tsakona CP, Jewel AP, Hoffbrand AV, Milligan DW, Burnett AK, Lewis ML, Goldstone AH.

Low dose recombinant alpha-2-interferon - a feasible maintenance therapy in acute myeloid leukaemia in the older patient.

Acta Haematologica. 89:1-5. 1993.

115. Rassam SMB, Turker A, Powles RL, Smith AG, Newland AC, Erskine JG, Pearce RM, Goldstone AH.

Idarubicin for remission induction of acute myeloid leukaemia - United Kingdom multicentre experience.

Seminars in Oncology. 20:13-19. 1993.

115. Tsakona CP, Khwaja A, Goldstone AH.

Does treatment with haematopoietic growth factors affect the incidence of bacteraemia in adult lymphoma transplant recipients.  
Bone Marrow Transplantation 11:433-436. 1993.

116. Tsakona CP, Khwaja A, Goldstone AH.  
Mean myeloperoxidase index in lymphoma transplants receiving recombinant granulocyte-macrophage colony stimulating factor.  
Bone Marrow Transplantation. 11:345-346. 1993

117. Gale RE, Wheadon H, Goldstone AH, Burnett AK, Linch DC.  
Frequency of clonal remission in acute myeloid leukaemia.  
Lancet 341:138-142. 1993.

118. Khwaja A, Mills W, Leveridge K, Goldstone AH, Linch DC.  
Efficacy of delayed granulocyte colony stimulating factor after autologous BMT.  
Bone Marrow Transplantation. 11:479-482. 1993

119. Lim SH, Smith MP, Machin SJ, Goldstone AH.  
A prospective randomised study of prophylactic Teicoplanin to prevent early Hickman catheter related sepsis in patients receiving intensive chemotherapy for haematological malignancies.  
European Journal of Haematology. 51:10-13. 1993

120. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, Mcmillan A, Chopra R, Milligan D, Hudson GV.  
Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin-s disease - results of a BNLI randomised trial.  
Lancet. 341:1051-1054.1993.

121. Tsakonas DP, Tsakona CP, Worman CP, Goldstone AH, Nicolaides KH.  
Myeloperoxidase activity and nuclear segmentation of maternal neutrophils during normal pregnancy.  
Clinical and Laboratory Haematology. 16:337-342. 1994.

122. Williams CD, Pearce R, Tahipour G, Green ES, Philip T, Goldstone AH.  
Autologous bone marrow transplantation for patients with non Hodgkin's lymphoma and CNS involvement - those transplanted with active CNS disease have a poor outcome - a report by the European bone marrow transplant lymphoma registry.  
Journal of Clinical Oncology 12:2415-2422. 1994.

123. Williams CD, Mcsweeney EN, Mills W, Wells P, Richards JDM, Tobias JS, Goldstone AH.  
Autologous bone marrow transplantation in multiple myeloma - a single centre experience of 23 patients.  
Leukaemia and Lymphoma 15:273-279. 1994.

124. Bacigalupo A, Chple M, Hows J, Vanlint MT, McCann S, Milligan D, Chessells J, Goldstone AH, Ottolander J, Vantveer ET, Commotti B, Coser P, Broccia G, Bosi A, Locasciulli A, Catalano L, Battista R, Arcese W, Carotenuto M, Marmont AM, Smith ECG.  
Treatment of aplastic anaemia (AA) with antilymphocyte globulin (ALG) and methylprednisolone (MPRED) with or without androgens - a randomised trial from the EBMT-SAA working party.  
*British Journal of Haematology*. 83:145-151. 1993.
125. Brink NS, Chopra R, Perrons CJ, Ring CJA, Garson JA, Briggs EM, Goldstone AH, Linch DC, Tedder RS.  
Efficacy of donor screening for hepatitis C antibodies in preventing hepatitis C infection in multiply transfused patients.  
*Transfusion Medicine*. 3:291-294. 1993.
126. Brink NS, Chopra R, Perrons CJ, Ring CJA, Garson JA, Briggs EM, Goldstone AH, Linch DC, Tedder RS.  
Acute hepatitis C infection in patients undergoing therapy for haematological malignancies - a clinical and virological study.  
*British Journal of Haematology*. 83:498-503. 1993
127. Chatterjee R, Mills W, Katz M, MCGarrigle HH, Goldstone AH.  
Induction of ovarian function by using short term human menopausal gonadotrophin in patients with ovarian failure following cytotoxic chemotherapy for haematological malignancy.  
*Leukaemia and Lymphoma*. 10:383-386. 1993.
127. Chopra R, Mcmillan AK, Linch DC, Yuklea S, Taghipour G, Pearce R, Patterson KG, Goldstone AH.  
The place of high dose beam therapy and autologous bone marrow transplantation in poor risk Hodgkin's disease - a single centre 8 year study of 155 patients.  
*Blood*. 81:1137-1145. 1993.
128. Ehrenstein MR, Mcsweeney E, Swana M, Worman CP, Goldstone AH, Isenberg DA.  
Appearance of anti DNA antibodies in patients treatment with interferon alpha.  
*Arthritis and Rheumatism*. 36:279-280. 1993.
129. Ljungman P, Biron P, Bosi A, Cahn JY, Goldstone AH, Gorin NC, Link H, Messina C, Michallet M, Richard C, Verdonck L,  
Cytomegalovirus interstitial pneumonia in autologous bone marrow transplant recipients.  
*Bone Marrow Transplantation*. 13:209-21. 1994
130. Mcsweeney EN, Giles FJ, Goldstone AH.  
Recombinant interferon-alpha (2) antibodies in chronic lymphocytic leukaemia.

Journal of Interferon Research. 14:191-192. 1994.

131. Mills W, Chatterjee R, MCGarrigle HHG, Linch DC, Goldstone AH.  
Partial hypopituitarism following total body irradiation in adult patients with  
haematological malignancy.

Bone Marrow Transplantation. 14:471-473. 1994

132. Mills W, Chopra R, Linch DC, Goldstone AH.

Liposomal amphotericin-b in the treatment of fungal infections in neutropenic  
patients - a single centre experience of 133 episodes in 116 patients.

British Journal of Haematology. 86:754-760. 1994.

133. Salooja N, Chatterjee R, Mcmillan AK, Kelsey SM, Newland AC,  
Milligan DW, Franklin IM, Hutchinson RM, Linch DC, Goldstone AH.

Successful pregnancies in women following single auto transplant for acute  
myeloid leukaemia with a chemotherapy ablation protocol.

Bone Marrow Transplantation. 13:431-435. 1994.

134. Sweetenham JW, Pearce R, Philip T, Proctor SJ, Mandelli F, Colombat  
P, Goldstone AH.

High dose therapy and autologous bone marrow transplantation for  
intermediate grade and high grade non Hodgkin's lymphoma in patients aged  
55 years and over - results from the European group for bone marrow  
transplantation.

Bone Marrow Transplantation. 14:981-987. 1994

135. Sweetenham W, Liberti G, Pearce R, Taghipour G, Santini G, Goldstone  
AH.

High dose therapy with autologous bone marrow transplantation for adult  
patients with lymphoblastic lymphoma - results of the European Group for  
Bone Marrow Transplantation.

Journal of Clinical Oncology. 12:1358-1365. 1994.

136. Chatterjee R, Mills W, Katz M, MCGarrigle HH, Goldstone AH.

Germ cell failure and Leydig cell insufficiency in post pubertal males after  
autologous bone marrow transplantation with beam for lymphoma.

Bone Marrow Transplantation. 13:511-517. 1994.

137. Chatterjee R, Mills W, Katz M, MCGarrigle HH, Goldstone AH.

Prospective study of pituitary gonadal function to evaluate short term effects  
of ablative chemotherapy or total body irradiation with autologous or  
allogenic marrow transplantation in post menarcheal female patients.

Bone Marrow Transplantation. 13:511-517. 1994.

138. Chopra R, Wotherspoon AC, Blair S, Mcmillan AK, Mills W, Fielding  
AK, Linch DC, Goldstone AH.

Detection and significance of bone marrow infiltration at the time of  
autologous bone marrow transplantation in Hodgkin's disease.

British Journal of Haematology. 87:647-649. 1994.

139. Grimwade DJ, Chopra R, King A, Shaw P, Pearce R, Linch DC, Goldstone AH.  
Detection and significance of pulmonary Hodgkin's disease and autologous bone marrow transplantation.  
*Bone Marrow Transplantation*. 13:173-179. 1994.
140. Jewell AP, Worman CP, Lydyard PM, Yong KL, Giles FJ, Goldstone AH.  
Interferon alpha up regulates BCL-2 expression and protects B-CLL cells from apoptosis in vitro and in vivo.  
*British Journal of Haematology*. 88:268-274. 1994.
141. Jewell AP, Yong KO, Worman CP, Tsakona CP, Giles FJ, Goldstone AH.  
Serum macrophage colony stimulating factor (M-CSF) levels correlate with clinical response to interferon alpha in patients with early stage B-CLL.  
*British Journal of Haematology*. 86:441-443.
142. Jones HM, Jones SA, Watts MJ, Khwaja A, Mills W, Fielding A, Goldstone AH, Linch DC,  
Development of a simplified single-apheresis approach for peripheral blood progenitor cell transplantation in previously treated patients with lymphoma.  
*Journal of Clinical Oncology*. 12:1693-1702. 1994.
143. Mills W, Strang J, Goldstone AH, Linch DC.  
Dose intensification of etoposide in the BEAM ABMT protocol for malignant lymphoma.  
*Leukaemia & Lymphoma*. 17:263-270. 1995.
144. Mills W, Chopra R, Mcmillan A, Pearce R, Linch DC, Goldstone AH.  
Beam chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non Hodgkin's lymphoma.  
*Journal of Clinical Oncology*. 13:588-595. 1995.
145. Tedder RS, Zuckerman MA, Goldstone AH, Hawkins AE, Fielding A, Briggs EM, Irwin D, Blair S, Gorman AM, Patterson KG, Linch DC, Heptonstall J, Brink NS.  
Hepatitis B transmission from contaminated cryopreservation tank.  
*Lancet*. 346:137-140. 1995.
146. Tsakonas DP, Nicolaides KH, Tsakona CP, Worman CP, Goldstone AH.  
Changes in maternal plasma macrophage colony stimulating factor levels during normal pregnancy.  
*Clinical and Laboratory Haematology*. 17:57-59. 1995.
147. Watts MJ, Jones HM, Sullivan AM, Langabeer SE, Jamieson E, Fielding A, Williams C, Berenson RJ, Goldstone AH, Linch DC.  
Accessory cells do not contribute to G-CSF or transplantation.

British Journal of Haematology. 91:767-772. 1995.

148. Bjorkstrand B, Goldstone AH, Ljungman P, Brandt L, Brunet S, Carlson K, Prentice HG, Cavo M, Samson D, deLaurenzi A, Verdonck LF, Proctor S, Ferrant A, Sierra J, Auzanneau G, Troussard X, Gravett P, Remes K, Gahrton G.

Prognostic factors in autologous stem cell transplantation for multiple myeloma - an EBMT registry study.

Leukaemia & Lymphoma. 15:265-272. 1994.

149. Castenskiold EC, Kelsey SM, Collins PW, Coldwell RD, Allen PD, Side LE, Makin HLJ, Goldstone AH, Newland AC.

Functional hyperactivity of monocytes after bone marrow transplantation - possible relevance for the development of post-transplant complications or relapse.

Bone Marrow Transplantation. 15:879-884. 1995.

150. Jewell AP, Lydyard PM, Worman CP, Giles FJ, Goldstone AH.

Growth factors can protect B-chronic lymphocytic leukaemia cells against programmed cell-death without stimulating proliferation.

Leukaemia & Lymphoma. 18:159-162. 1995.

151. Khwaja A, Goldstone AH, Linch DC.

Delayed neutrophil recovery after beam chemotherapy and autologous bone marrow transplantation for lymphoma is not associated with increased mortality from infection.

Bone Marrow Transplantation. 15:313-315. 1995.

152. Williams CD, Goldstone AH, Pearce RM, Philip T, Hartmann O, Colombat P, Santini G, Foulard L.

Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma - a case matched comparison with unpurged cases by the European Blood and Marrow Transplant lymphoma registry.

Journal of Clinical Oncology. 14:2454-2464. 1995.

153. Boogaerts MA, Demuynck H, Mestdagh N, Verbist L, Goldstone AH, Kelsey HC, Machin S, Depauw BE, Donnelly JP, Raemaekers JMM, Atkinson G, Williams KJ.

Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients.

Journal of Antimicrobial Chemotherapy. 36:185-200. 1995.

154. Bradley SJ, Pearce R, Taghipour G, Vaughanhudson B, Goldstone AH.

First remission of autologous bone marrow transplantation for Hodgkin's disease - preliminary EBMT data.

Leukaemia & Lymphoma. 15:51-53. 1995.

155. Milpied N, Fielding AK, Pearce RM, Ernst P, Goldstone AH.

Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin-s disease.  
Journal of Clinical Oncology 14:1291-1296. 1996.

156. Porwitmacdonald A, Janossy G, Ivory K, Swirsky D, Peters R, Wheatley K, Walker H, Turker A, Goldstone AH, Burnett A.  
Leukaemia associated changes identified by quantitative flow cytometry. 4. cd34 over expression in acute myelogenous leukaemia M2 with t(8;21).  
Blood 87:1162-1169. 1996.

157. Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, Demuyneck HMS, Link H, Zander A, Barge A, Borkett K.  
Randomised trial of filgrasim-mobilized peripheral blood progenitor cell transplantation versus autologous bone marrow transplantation in lymphoma patients.  
Lancet. 347:353-357. 1996.

158. Slevin ML, Nichols SE, Downer SM, Wilson P, Lister TA, Arnott S, Maher J, Souhami RL, Tobias JS, Goldstone AH, Cody M.  
Emotional support for cancer patients - what do patients really want.  
British Journal of Cancer. 74:1275-1279. 1996.

168. Sweetenham JW, Taghipour G, Milligan D, Goldstone AH.  
Adult burkitt and burkitt like non-Hodgkin's lymphoma - outcome for patients treated with high dose therapy and autologous stem cell transplantation in first remission or at relapse - results from the European group for blood and marrow transplantation.  
Journal of Clinical Oncology. 14:2465-2472. 1996.

159. Sweetenham JW, Taghipou G, Milligan D, Goldstone AH.  
Adult Burkitt and Burkitt like non-Hodgkin's lymphoma - outcome for patients treated with high dose therapy and autologous stem cell transplantation in first remission or at relapse - results from the European group for blood and marrow transplantation.  
Journal of Clinical Oncology. 14:22465-2472. 1996.

160. Fielding AK, Goldstone AH, Sullivan AM, Watts MJ, Jamieson E, Linch DC.  
Peripheral blood stem cell support doses not accelerate haematopoietic recovery from minibeam chemotherapy.  
Bone Marrow Transplantation. 18:507-511. 1996.

161. Gale RE, Bunch C, Moir DJ, Patterson KG, Goldstone AH, Linch DC.  
Demonstration of developing myelodysplasia acute myeloid leukaemia in haematologically normal patients after high dose chemotherapy and autologous bone marrow transplantation using X chromosome inactivation patterns.  
British Journal of Haematology. 93:53-58. 1996.

162. Gorin NC, Labopin M, Foullard L, Meloni G, Fassoni F, Iriando A, Mauri SB, Goldstone AH, Harousseau JL, Reiffers J, Esperoubeurdeau H, Gluckman E.

Retrospective evaluation of autologous bone marrow transplantation versus allogeneic bone marrow transplantation from an identical related donor in acute myelocytic leukaemia - a study of the European cooperative group for blood and marrow transplantation (BMT).

Bone Marrow Transplantation. 18:111-117. 1996.

163. Hawkins AE, Zuckerman MA, Briggs M, Gilson RJC, Goldstone AH, Brink NS, Tedder RS.

Hepatitis-B nucleotide sequence analysis - linking an outbreak of acute hepatitis B to contamination of cryopreservation tank.

Journal of Virological Methods. 60:81-88. 1996.

164. Agular RCT, Sohal J, vanRhee F, Carapeti M, Franklin IM, Goldstone AH, Goldman JM, Cross NCP.

Tel-AML 1 fusion in acute lymphoblastic leukaemia of adults.

British Journal of Haematology. 96:673-677. 1996.

165. Bjorkstrand B, Ljungman P, Svensson H, Hermans J, Alegre A, Apperley J, Blade J, Carlson K, Cavo M, Ferrant A, Goldstone AH, deLaurenzi A, Majolino I, Marcus R, Prentice HG, Remes K, Samson D, Sureda A, Verdonck LF, Volin L, Gahrton G.

Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case matched study from the European group for blood and marrow transplantation.

Blood 88:4711-4718. 1996.

166. Grimwade D, Howe K, Langabeer S, Davies L, Oliver F, Walker H, Swirsky D, Wheatley K, Goldstone AH, Burnett A, Solomon E.

Establishing the presence of the t(15;17) in suspected acute promyelocytic leukaemia: cytogenetic, molecular and PML immunofluorescence assessment of patients entered into the MRC ATRA trial. MRC Adult Leukaemia Working Party.

British Journal of Haematology. 94(3):557-73. 1996.

167. Grimwade D, Howe K, Langabeer S, Burnett A, Goldstone AH, Solomon E.

Minimal residual disease detection in acute promyelocytic leukaemia by reserve-transcriptase PCR: evaluation of PML-RAR alpha and RAR alpha-PML assessment in patients who ultimately relapse.

Leukaemia 10(1):61-6. 1996.

168. Langabeer SE, Walker H, Gale RE, Wheatley K, Burnett AK, Goldstone AH, Linch DC.

Frequency of CBF beta;myh11 fusion transcripts in patients entered into the UK MRC AML trials.

British Journal of Haematology. 96:736-739. 1997.

169. Linch DC, Milligan DW, Winfield DA, Kelsey SM, Johnson SA, Littlewood TJ, Smith GM, Hutchinson RM, Goldstone AH, Fielding AK, Hudson GV.  
G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomised BNLI trial.  
*British Journal of Haematology*. 99:933-938. 1997.
170. Majolino K, Pearce R, Taghipour G, Goldstone AH.  
Peripheral blood stem cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: a new matched pair analysis of European group for blood and marrow transplantation registry data.  
*Journal of Clinical Oncology*. 15:509-517. 1997.
171. Nokes TJC, Johnson S, Harvey D, Goldstone AH.  
FLAG is a useful regimen for poor prognosis adult myeloid leukaemias and myelodysplastic syndromes.  
*Leukaemia & Lymphoma*. 27:93-101. 1997.
172. Paietta E, Racevskis J, Neuberger D, Rowe JM, Goldstone AH, Wiernik PH.  
Expression of cd25 (interleukin-2 receptor alpha chain) in adult acute lymphoblastic leukaemia predicts for the presence of bcr;abl fusion transcripts: results of a preliminary laboratory analysis of ECOG/MRC intergroup study E2993.  
*Leukaemia* 11: 1887-1890. 1997.
173. Smith TJ, Hilner B, Schimitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, Link H, Zander A, Yanovich S, Kitchin R, Erder MH.  
Analysis of a randomised clinical trial to compare filgrastim mobilised peripheral blood progenitor cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non Hodgkin's lymphoma.  
*Journal of Clinical Oncology*. 15:5-10. 1997.
174. Sweetenham JW, Bierman P, Taghipour G, Gratwohi A, Hagenbeek A, Greinix H, Schaefer UW, Goldstone AH.  
Two thirds of adult patients (pts) with lymphoma achieve long term survival after syngeneic bone marrow transplantation (BMT) - results from the EBMT.  
*Bone Marrow Transplantation*. 20:745-752. 1997.
175. Vandenberghe E, Pearce R, Taghipour G, Foulliard L, Goldstone AH.  
Role of a second transplant in the management of poor prognosis lymphomas: a report from the European blood and bone marrow registry.  
*Journal of Clinical Oncology*. 15:1595-1600. 1997.

176. Watts MJ, Sullivan AM, Ings SJ, Leverett D, Peniket AJ, Perry AR, Williams CD, Devereux S, Goldstone AH, Linch DC.  
Evaluation of clinical scale CD34(+) cell purification: experience of 71 immunoaffinity column procedures.  
Bone Marrow Transplantation. 20:157-162, 1997
177. Watts MJ, Sullivan AM, Jamieson E, Pearce R, Fielding A, Devereux S, Goldstone AH, Linch DC.  
Progenitor cell mobilisation after low dose cyclophosphamide and granulocyte colony stimulating factor: an analysis of progenitor cell quantity and quality and factors predicting for these parameters in 101 pre-treated patients with malignant lymphoma.  
Journal of Clinical Oncology. 15:535-546. 1997.
178. Chalmers EA, Franklin IM, Kelsey SR, Newland AC, Clarke RE, Sproul AN, Crotty G, McCann SR, Fielding A, Goldstone AH, Heppleston A, Watson W, Sharp RA, Tansey P.  
Treatment of chronic myeloid leukaemia in first chronic phase with Idarubicin and cytarabine: mobilisation of Philadelphia negative peripheral blood stem cells.  
British Journal of Haematology. 96:627-634. 1997.
179. Grimwade D, Gorman P, Duprez E, Howe K, Langabeer S, Oliver F, Walker H, Culligan D, Waters J, Pomfret M, Goldstone AH, Burnett A, Freemont P, Sheer D, Solomon E.  
Characterisation of cryptic rearrangements and variant translocations in acute promyelocytic leukaemia.  
Blood. 90(12):4876-85. 1997.
180. Grimwade D, Walker H, Oliver F, Wheatley K, Clack R, Burnett A, Goldstone AH.  
What happens subsequently in AML when cytogenetic abnormalities persist at bone marrow harvest? Results of the 10th UK MRC AML trial. Medical Research Council Leukaemia Working Parties.  
Bone Marrow Transplant. 19(11):1117-23. 1997
181. Hann IM, Stevens RF, Goldstone AH, Rees JKH, Wheatley K, Gray RG, Burnett AK.  
Randomised comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukaemia. Results of the MRC 10th AML trial (MRC AML10). Blood 89:2311-2318. 1997.
182. Jewell AP, Worman CP, Giles FJ, Goldstone AH.  
Serum levels of TNF, il-6 and sCD23 correlate with changes in lymphocyte count in patients with B cell chronic lymphocytic leukaemia receiving interferon alpha therapy.  
Leukaemia & Lymphoma. 24:327-333. 1997.

183. Langabeer SE, Walker H, Rogers JR, Burnett AK, Wheatley K, Swirsky D, Goldstone AH, Linch DC.  
Incidence of AML-1/ETO fusion transcripts in patients entered into the MRC AML trials.  
British Journal of Haematology. 99:925-928. 1997.
184. Rees D, Grimwade D, Langabeer S, Burnett A, Goldstone AH.  
Influence of genetic predisposition to thrombosis on natural history acute promyelocytic leukaemia. MRC Adult Leukaemia Working Party.  
British Journal of Haematology. 96(3):490-2. 1997.
185. Belkacemi Y, Labopin M, Vernant JP, Prentice HG, Tichelli A, Schattenberg A, Boogaerts MA, ERnst P, Della Volpe, Goldstone AH, Joet JP, Verdonck LF, Losasciulli A, Rio B, Ozsahin M, Gorin NC.  
Cataracts after total body irradiation and bone marrow transplantation in patients with acute leukaemia in complete remission: a study of the European Group for Blood and Marrow Transplantation.  
International Journal of Radiation Oncology, Biology, Physics. 41(3):659-68. 1998.
186. Burnett AK, Goldstone AH, Stevens RM, Hann IM, Rees JK, Gray RG, Wheatley K.  
Randomised comparison of addition of autologous bone marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties.  
Lancet 351(9104):700-8, 1998.
187. Devereux S, Corney C, Macdonald C, Watts M, Sullivan A, Goldstone AH, Ward M, Bank A, Linch DC.  
Feasibility of multidrug resistance (MDR-1) gene transfer in patients undergoing high-dose therapy and peripheral blood stem cell transplantation for lymphoma.  
Gene Therapy. 5(3):403-8. 1998.
188. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone AH.  
The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.  
Blood. 1;92:2322-33. 1998.
189. Langabeer SE, Grimwade D, Walker H, Rogers JR, Burnett AK, Goldstone AH, Linch DC.  
A study to determine whether trisomy 8, deleted 9q and trisomy 22 are markers of cryptic rearrangements of PML/RARalpha, AML1/ETO and CBFβ/MYH11 respectively in myeloid leukaemia. MRC Adult Leukaemia Working Party. Medical Research Council.  
British Journal of Haematology. 101(2):338-40. 1998.

190. Perry AR, Watts MJ, Peniket AJ, Goldstone AH, Linch DC.  
Progenitor cell yields are frequently poor in patients with histologically indolent lymphomas especially when mobilised within 6 months of previous chemotherapy.  
Bone Marrow Transplantation. 21:(12):1201-5. 1998.
191. Watts MJ, Sullivan AM, Leverett D, Peniket AJ, Perry AR, Williams CD, Devereux S, Goldstone AH, Linch DC.  
Back up bone marrow is frequently ineffective in patients with poor peripheral blood stem cell mobilisation.  
Journal of Clinical Oncology 16(4):1554-60. 1998.
192. Watts MJ, Sullivan AM, Ings SJ, Barlow M, Devereux S, Goldstone AH, Linch DC.  
Storage of PBSC at -80 degrees C.  
Bone marrow transplant. 1998 Jan; 21(1): 111-2.
193. Burnett AK, Goldstone AH, Stevens RM, Hann IM, Rees JK, Gray RG, Wheatley  
Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial.  
UK Medical Research Council Adult and Children's Leukaemia. Working Parties.  
Lancet. 1998. Mar 7;351(9104):700-8
194. Watts MJ, Sullivan AM, Leverett D, Peniket AJ, Perry AR, Williams CD, Devereux S, Goldstone AH, Linch DC.  
Back-up bone marrow is frequently ineffective patients with poor peripheral blood stem cell mobilisation.  
J Clin Oncol. 1998 Apr; 16(4):1554-60.
195. Langabeer SE, Grimwade D, Walker H, Rogers JR, Burnett AK, Goldstone AH, Linch DC.  
A study to determine whether trisomy 8, deleted 9q and trisomy 22 are markers of cryptic rearrangements of PML/RARalpha, AML1/ETL and CBFβ/MYH11 respectively in acute myeloid leukaemia.  
MRC adult working party. Medical Research Council.  
Br J Haematol. 1998; 101(2):338-40.
196. Devereux S, Corney C, Macdonald C, Watts M, Sullivan A, Goldstone AH, Ward M, Bank A, Linch DC.  
Feasibility of multidrug resistance (MDR-1) gene transfer in patients undergoing high dose therapy and peripheral blood stem cell transplantation for lymphoma.  
Gene Ther. 1998 Mar; 5(3) : 403-8

197. Belkacemi Y, Labopin M, Vernant JP, Prentice HG, Tichelli A, Schattenberg A, Boogaerts MA, Ernst P, Della Volpe A, Goldstone AH, Jouet JP, Verdonck LF, Locasciulli A, Rio B, Ozsahin M, Gorin NC.  
Cataracts after total body irradiation and bone marrow transplantation in patients with acute leukaemia in complete remission: a study of the European Group for Blood and Marrow Transplantation.  
Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3) : 659-58.
198. Perry AR, Watts MJ, Peniket AJ, Goldstone AH, Linch DC.  
Progenitor cell yields are frequently poor in patients with histologically indolent lymphomas especially when mobilised within 6 months of previous chemotherapy.  
Bone marrow transplant. 1998 Jun;21 (12) : 1201-5.
199. Peniket AJ, Perry, AR, Williams CD, Macmillan A, Watts MJ, Issacson PG, Goldstone AH, Linch DC.  
A case of EBV associated lymphoproliferative disease following high dose therapy and CD34 purified autologous peripheral blood progenitor cell transplantation.  
Bone marrow transplant. 1998 Aug; 22(3) ; 307-9.
200. Murphy MF, Murphy W, Wheatley K, Goldstone AH  
Survey of the use of platelet transfusions in centres participating in MRC leukaemia trials.  
Br J Haematol. 1998 Aug; 102(3) : 875-6.
201. Singer IO, Franklin IM, Clark RE, Chalmers EA, Kelsey SM, Newland AC, Sproul AM, Crotty G, McCann SR, Goldstone AH, McBride N, Hepplestone A, Watson W, Sharp RA, Tansey PJ.  
Autologous transplantation in chronic myeloid leukaemia using peripheral blood stem cells.  
Br J Haematol. 1998 Sep;102 (5) : 1359-62
202. Fanin R, Ruiz de Elvira MC, Sperotto A, Baccarani M, Goldstone AH.  
Autologous stem cell transplantation for T and null cell CD30 positive anaplastic large cell lymphoma; analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT).  
Bone Marrow Transplant. 1999 Mar; 23 (5) : 434-42.
203. Kottaridis PD, Rees H, Smith G, Garner SF, Perry AR, Peniket AJ, Goldstone AH, Mackinnon S, Ouweland WH.  
A fatal case of autoimmune thrombocytopenia with an IgM anti-GPIb/IX following one antigen mismatched unrelated donor bone marrow transplantation.  
Bone Marrow Transplant. 1999 Apr; 23(7) : 739-41.

204. Allford S, Grimwade D, Langabeer S, Duprex E, Saurin A, Chatters S, Walker H, Roberts P, Rogers J, Bain B, Patterson K, McKernan A, Freemont P, Solomon E, Burnett A, Goldstone AH, Linch D.  
Identification of the t (15;17) in AML FAB types other than M3: evaluation of the role of molecular screening for the PML/RARalpha rearrangement in newly diagnosed AML.  
The Medical Research Council (MRC) Adult Leukaemia Working Party.  
Br J Haematol. 1999 Apr; 105(1) : 198-207.
205. Perry AR, Peniket AJ, Watts MJ, Leverett D, Goldstone AH, Linch DC.  
Peripheral blood stem cell versus autologous bone marrow transplantation for Hodgkin's disease: equivalent survival outcome in a single centre matched pair analysis.  
Br J Haematol. 1999 Apr; 105(1) : 280-7.
206. Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH.  
Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukaemia treated with all-trans retinoic acid: result of the randomised MRC trial.  
Blood. 1999 Jun15; 93(12) : 4131-43.
207. Perry AR, Rivlin MM, Goldstone AH  
Bone marrow transplant patients with life threatening organ failure: when should treatment stop?  
J Clin Oncol. 1999 Jan; 17(1) : 298-303.
208. Sweetenham JW, Carella AM, Taghipour G, Cunningham D, Marcus R, Della Volpe A, Linch DC, Schmitz N, Goldstone AH.  
High dose therapy and autologous stem cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party.  
J Clin Oncol. 1999 Oct; 17(1) : 3101-9.
209. Watson M, Wheatley K, Harrison GA, Zittoun R, Gray RG, Goldstone AH, Burnett AK.  
Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone: analysis of the MRC AML 10 trial.  
Cancer. 1999 Oct 1; 86(7) : 1231-9.
210. Harrison CN, Gregory W, Hudson GV, Devereux S, Goldstone AH, Hancock B, Winfield D, Macmillan AK, Hoskin P, Newland AC, Milligan D, Linch DC.  
High dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.  
Br J Cancer. 1999 Oct; 81 (3) : 476-83.

211. Kottaridis PD, Ketley N, Peggs K, Chakraverty R, Ralleigh G, Shaw P, Pezzella F, Goldstone AH, Devereux S, Mackinnon S.  
An unusual case of intrapulmonary granulocytic sarcoma presenting as interstitial pneumonitis following allogeneic bone marrow transplantation for acute myeloid leukaemia and responding to donor lymphocyte infusion.  
Bone Marrow Transplant. 1999 Oct; 24(7) : 807-9
212. Milligan DW, Ruiz De Elvira MC, Kolb JH, Goldstone AH, Meloni G, Rohatiner AZ, Colombat P, Schmitz N.  
Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT.  
EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Bone Marrow Transplantation.  
Br J Haematol. 1999 Sept; 106 (4) : 1020-6.
213. Wheatley K, Burnett AK, Goldstone AH, Gray RG, Hann IM, Harrison CJ, Rees JK, Stevens RF, Walker H.  
A simple, robust, validated and highly predictive index for the determination of risk directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial.  
United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties.  
Br J Haematol. 1999 Oct; 107(1) : 69-79.
233. Bradley SJ, Wilson AL, Allen MC, Sher HA, Goldstone AH, Scott GM.  
The control of hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage.  
J Antimicrob Chemother. 1999 Feb;43(2):261-6.
214. Watts MJ, Ings SJ, Leverett D, Macmillan A, Devereux S, Goldstone AH, Linch DC.  
ESHAP and G-CSF is a superior blood stem cell mobilising regimen compared to cyclophosphamide 1.5 g m (-2) and G-CSF for pre treated lymphoma patients: a matched pairs analysis of 78 patients.  
Br J Cancer. 2000 Jan; 82(2) : 278-82.
215. Clark R, Byatt SA, Bennett CF, Brama M, Martineau M, Moorman AV, Roberts K, Secker-Walker LM, Richards S, Eden OB, Goldstone AH, Harrison CJ.  
Monosomy 20 as a pointer to dicentric (9;20) in acute lymphoblastic leukaemia.  
Leukaemia. 2000 Feb; 14(2) : 241-6.
216. Pezzella F, Munson PJ, Miller KD, Goldstone AH, Gatter KC.  
The diagnosis of low grade peripheral B cell neoplasms in bone marrow trephines.  
Br J Haematol. 2000 Feb; 108(2) : 369-76.

217. Kottaridis PD, Peggs K, Lawrence A, Verfuert S, Chatterjee R, Telfer P, Porter JB, Mackinnon S, Goldstone AH.  
One antigen mismatched related donor bone marrow transplant in a patient with acute lymphoblastic leukaemia and beta-thalassaemia major: potential cure of both marrow disorders.  
Bone Marrow Transplant. 2000 Mar; 25(6) : 677-8.
218. Chatterjee R, Haines GA, Perera DM, Goldstone A, Morris ID.  
Testicular and sperm DNA damage after treatment with fludarabine for chronic lymphocytic leukaemia.  
Hum Reprod. 2000 Apr; 15(4) : 762-6.
219. Harvey CJ, Peniket AJ, Miszkiet K, Patterson K, Goldstone AH, Mackinnon S, Hall-Craggs MA.  
MR angiographic diagnosis of cerebral venous sinus thrombosis following allogeneic bone marrow transplantation.  
Bone Marrow Transplant. 2000 Apr; 25(7) : 791-5.
220. Chatterjee R, Kottaridis PD, Lees WR, Ralph DJ, Goldstone AH.  
Cavernosal arterial insufficiency and erectile dysfunction in recipients of high dose chemotherapy and total body irradiation for multiple myeloma.  
Lancet. 2000 Apr 15; 353(9212) : 1335-6.
221. Iqbal S, Grimwade D, Chase A, Goldstone AH, Burnett A, Goldman JM, Swirsky D.  
Identification of PML/RARalpha rearrangements in suspected acute promyelocytic leukaemia using fluorescence in situ hybridisation of bone marrow smears: a comparison with cytogenetics and RT-PCR in MRC ATRA trial patients. MRC Adult Leukaemia Working Party.  
Leukaemia. 2000 May; 14(5) : 950-3.
222. Foran JM, Gupta RK, Cunningham D, Popescu RA, Goldstone AH, Sweetenham JW, Pettengell R, Johnson PW, Bessell E, Hancock B, Sumers K, Hughes J, Rohatiner AZ, Lister TA.  
At UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response.  
Br J Haematol. 2000 Apr; 109(1) : 81-8.
223. Chatterjee R, Andrews HO, McGarrigle HH, Kottaridis PD, Lees WR, Mackinnon S, Ralph DJ, Goldstone AH.  
Cavernosal arterial insufficiency is a major component of erectile dysfunction in some recipients of high dose chemotherapy/chemo-radiotherapy for haematological malignancies.  
Bone Marrow Transplant. 2000 Jun; 25(11) : 1185-9.
224. Peggs KS, Ings SJ, Kottaridis PD, Yong K, Williams CD, Goldstone AH, Mackinnon S.

Cytomegalovirus infection and disease after autologous CD34 selected peripheral blood stem cell transplantation for multiple myeloma: no evidence of increased incidence based on polymerase-chain-reaction monitoring. *Blood*. 2000 Jul 1; 96(1) : 369-70.

225. Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, Peggs K, Verfuert S, Pettengell R, Marsh JC, Schey S, Mahendra P, Morgan GJ, Hale G, Waldmann H, de Elvira MC, Williams CD, Devereux S, Linch DC, Goldstone AH, Mackinnon S.  
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. *Blood*. 2000 Oct 1; 96(7) : 2419-25.

226. Kottaridis PD, Peggs K, Devereux S, Goldstone AH, Mackinnon S.  
Simultaneous occurrence of clostridium difficile and cytomegalovirus colitis in a recipient of autologous stem cell transplantation. *Haematologica*. 2000 Oct; 85(10) : 1116-7.

229. Watts MJ, Ings SJ, Flynn M, Dodds D, Goldstone AH, Linch DC.  
Remobilization of patients who fail to achieve minimal progenitor thresholds at the first attempt is clinically worthwhile. *Br J Haematol*. 2000 Oct;111(1):287-91.

230. Peggs KS, Preiser W, Kottaridis PD, McKeag N, Brink NS, Tedder RS, Goldstone AH, Linch DC, Mackinnon S.  
Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation. *Br J Haematol*. 2000 Dec;111(3):782-90.

227. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE, et al.  
Attempts to improve treatment outcomes in acute myeloid leukaemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. *Blood* 2001; 98(5) : 1302-1311.

228. Chatterjee R, Kottaridis PD, McGarrigle H, Goldstone AH.  
Reversal of fludarabine induced testicular damage in a patient with chronic lymphocytic leukaemia (CLL), by suppression of pituitary-testicular axis using gonadotrophin releasing hormone (GnRH). *Leukaemia & Lymphoma*. 2001; 41(1-2) : 213-215

231. Williams CD, Harrison CN, Lister TA, Norton AJ, Blystad AK, Coiffier B, Taghipour G, Schmitz N, Goldstone AH.  
High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. *J Clin Oncol*. 2001 Feb 1;19(3):727-35.

232. Langabeer SE, Rogers JR, Harrison G, Wheatley K, Walker H, Bain BJ, Burnett AK, Goldstone AH, Linch DC, Grimwade D.  
EV11 expression in acute myeloid leukaemia.  
Br J Haematol. 2001 Jan;112(1):208-11.
234. Bjorkstrand B, Svensson H, Goldschmidt H, Ljungman P, Apperley J, Mandelli F, Marcus R, Boogaerts M, Alegre A, Remes K, Cornelissen JJ, Blade J, Lenhoff S, Iriando A, Carlson K, Volin L, Littlewood T, Goldstone AH, San Miguel J, Schattenberg A, Gahrton G. Related Articles  
Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT).  
Bone Marrow Transplant. 2001 Mar;27(5):511-5.
235. Sweetenham JW, Santini G, Qian W, Guelfi M, Schmitz N, Simnett S, Nagler A, Holte H, Kvaloy S, Bruzzi P, Goldstone AH.  
High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group.  
J Clin Oncol. 2001 Jun 1;19(11):2927-36.
236. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE.  
Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial.  
Blood. 2001 Sep 1;98(5):1302-11.
237. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, Wheatley K, Burnett AK, Goldstone AH.  
The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.  
Blood. 2001 Sep 1;98(5):1312-20.
238. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, Walker H, Wheatley K, Bowen DT, Burnett AK, Goldstone AH, Linch DC.  
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.  
Blood. 2001 Sep 15;98(6):1752-9.

239. Chatterjee R, Kottaridis PD, McGarrigle HH, Eliahoo J, McKeag N, Mackinnon S, Goldstone AH. Related Articles  
Patterns of Leydig cell insufficiency in adult males following bone marrow transplantation for haematological malignancies.  
Bone Marrow Transplant. 2001 Sep;28(5):497-502.
240. Chatterjee R, Kottaridis PD, McGarrigle HH, Papatryphonos A, Goldstone AH.  
Hypogonadotrophism fails to prevent severe testicular damage induced by total body irradiation in a patient with beta-thalassaemia major and acute lymphoblastic leukaemia.  
Bone Marrow Transplant. 2001 Nov;28(10):989-91.
241. Chakraverty R, Robinson S, Peggs K, Kottaridis PD, Watts MJ, Ings SJ, Hale G, Waldmann H, Linch DC, Goldstone AH, Mackinnon S.  
Excessive T cell depletion of peripheral blood stem cells has an adverse effect upon outcome following allogeneic stem cell transplantation.  
Bone Marrow Transplant. 2001 Nov;28(9):827-34.
242. Avivi I, Goldstone AH. Autologous stem cell transplantation in Hodgkin's disease. *Annals of Oncology* 2002;13 Suppl 1:122-7.
243. Branson K, Chopra R, Kottaridis PD, McQuaker G, Parker A, Schey S, et al. Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. *Journal of Clinical Oncology* 2002 Oct 1;20(19):4022-31.
244. Burnett AK, Wheatley K, Goldstone AH, Stevens RF, Hann IM, Rees JH, et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. *British Journal of Haematology* 2002 Aug;118(2):385-400.
245. Chakrabarti S, Mackinnon S, Chopra R, Kottaridis PD, Peggs K, O'Gorman P, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. *Blood* 2002 Jun 15;99(12):4357-63.
246. Chakrabarti S, Avivi I, Mackinnon S, Ward KN, Kottaridis PD, Osman H, et al. Respiratory virus infections in transplants recipients after reduced intensity conditioning with Campath-1H: High incidence but low mortality. *British Journal of Haematology* 2002;119:1125-32.
247. Chakraverty R, Peggs K, Chopra R, Milligan DW, Kottaridis PD, Verfuert S, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. *Blood* 2002 Feb 1;99(3):1071-8.
248. Jabber Al-Obaidi MS, Martineau M, Bennett CF, Franklin IM, Goldstone AH, Harewood L, et al. ETV6/AML1 fusion by FISH in adult acute lymphoblastic leukemia. *Leukemia* 2002 Apr;16(4):669-74.

249. Kottaridis PD, Peggs K, Schmitz N, Dreger P, Boogaerts MA, Ferrant A, et al. Survival and freedom from progression in autotransplant lymphoma patients is independent of stem cell source: further follow-up from the original randomised study to assess engraftment. *Leuk Lymphoma* 2002;43:531-6.
250. Perez-Simon JA, Kottaridis PD, Martino R, Craddock C, Caballero D, Chopra R, et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. *Blood* 2002 Nov 1;100(9):3121-7.
251. Schmitz N, Pfister B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. *Lancet* 2002 Jun 15;359(9323):2065-71.
252. Avivi I, Goldstone AH. Bone marrow transplant in Ph+ ALL patients. *Bone Marrow Transplantation* 2003 Apr;31(8):623-32.
253. D'Sa S, Peggs K, Pizzey A, Verfuether S, Thurai Sundaram D, Watts M, et al. T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor lymphocyte infusions. *British Journal of Haematology* 2003 Oct;123(2):309-22.
254. Morris EC, Rebello P, Thomson KJ, Peggs KS, Kyriakou C, Goldstone AH, et al. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications. *Blood* 2003 Jul 1;102(1):404-6.
255. Peggs KS, Verfuether S, Pizzey A, Khan N, Moss P, Goldstone AH, et al. Reconstitution of T-cell repertoire after autologous stem cell transplantation: influence of CD34 selection and cytomegalovirus infection. *Biology of Blood & Marrow Transplantation* 2003 Mar;9(3):198-205.
256. Peniket AJ, Ruiz de Elvira MC, Taghipour G, Cordonnier C, Gluckman E, de Witte T, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. *Bone Marrow Transplantation* 2003 Apr;31(8):667-78.
257. Vandenberghe E, Ruiz dE, Loberiza FR, Conde E, Lopez-Guillermo A, Gisselbrecht C, et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. *British Journal of Haematology* 2003 Mar;120(5):793-800
258. Avivi I, Chakrabarti S, Milligan DW, Waldmann H, Hale G, Osman H, et al. Incidence and outcome of adenovirus disease in transplant recipients

after reduced-intensity conditioning with alemtuzumab. *Biology of Blood and Marrow Transplantation* 2004;10(3):186-94.

259. Avivi I, Chakrabarti S, Kottaridis P, Kyriaku C, Dogan A, Milligan D, et al. Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation. *Bone Marrow Transplantation* 2004;Vol(Iss /Pg. 34/2):137-42.

260. Harrison CJ, Moorman A, V, Broadfield ZJ, Cheung KL, Harris RL, Jalali GR, et al. Three distinct subgroups of hypodiploidy in lymphoblastic leukaemia. *British Journal of Haematology* 2004 Jun 1;Vol(Iss /Pg. 125/5):552-9.

261. Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cook G, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. *Blood* 2004 Dec 15;104(13):3865-71.

262. Peggs KS, Thomson K, Hart DP, Geary J, Morris EC, Yong K, et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: Toxicity, chimerism, and disease responses. *Blood* 2004 Feb 15;103(4):1548-56.

263. Sa S, Yong K, Kyriakou C, Bhattacharya S, Peggs KS, Foulkes B, et al. Etoposide, methylprednisolone, cytarabine and cisplatin successfully cytoreduces resistant myeloma patients and mobilizes them for transplant without adverse effects. *British Journal of Haematology* 2004;125(6):756-65.

264. Watson M, Buck G, Wheatley K, Homewood JR, Goldstone AH, Rees J-KH, et al. Adverse impact of bone marrow transplantation on quality of life in acute myeloid leukaemia patients: Analysis of the UK Medical Research Council AML 10 Trial. *European Journal of Cancer* 2004;40(7):971-8

265. Ardeshtna KM, Kakouros N, Qian W, Powell MG, Saini N, D'Sa S, et al. Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first line salvage therapy regimens. *British Journal of Haematology* 2005;130:363-72.

266. Hart DP, Avivi I, Thomson KJ, Peggs KS, Morris EC, Goldstone AH, et al. Use of 18F-FDG positron emission tomography following allogeneic transplantation to guide adoptive immunotherapy with donor lymphocyte infusions. *British Journal of Haematology* 2005;-9.

267. Kyriakou C, Thomson KJ, D'Sa S, Flory A, Hanslip J, Goldstone AH, et al. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. *British Journal of Haematology* 2005;129(6):763-70.

268. Peggs KS, Hunter A, Chopra R, Parker A, Mahendra P, Milligan D, et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. *Lancet* 2005 Jun 4;365(9475):1934-41.

**C. OTHER PUBLICATIONS (Abstracts and letters)**

1. Janossy G, Greaves MF, Capellara D, Roberts M, Goldstone AH. 1977  
Membrane marker analysis of lymphoid and myeloid blast crisis in Phl positive CML.
2. Janossy G, McVerry BA, Goldstone AH, Souhami RL, Cawley JC, Thompson D. 1977.  
Atypical surface marker characteristics in a T-cell lymphoma.  
*Scand J. Haem.* 19:411.
3. Hazleman B, Goldstone AH, Voak D. 1977.  
Association of polymyalgia rheumatica and giant cell arteritis with HLA-38.  
*Brit. Med. J.* 2:989
4. Moran CJ, Parry HF, Mowbray J, Richards JDM, Goldstone AH. 1977.  
Plasmaphoresis in Systemic Lupus Erythematosus.  
*Brit. Med. J.* 2:1573.
5. Patterson KG, Goldstone AH, Richards JDM, Cawley JC. 1980.  
Studies of cell size in lymphoproliferative disorders.  
*Brit. J. Haem.* 46:337.
6. Mills KHG, Worman CP, Linch DC, Beverley PCL, Goldstone AH, Cawley JC.  
An increase of OKT8 & suppresser T-cells in megakaryocytic thrombocytopenia - the role of suppressor cells in the regulation of haematopoiesis.  
*British Journal of Haematology.* 50:683. 1982.
7. Souhami RL, Harper PG, Linch DC, Goldstone AH, Richards JDM, Trask C, Tobias JS, Spiro SG, Geddes DM.  
Single agent high dose cyclophosphamide with autologous bone marrow transfusion (ABMT) as initial treatment for small cell carcinoma of the bronchus (SCCB).  
*Thorax.* 37:783. 1982.
8. Knight RA, Stephens HAF, Addison IE, Goldstone AH.  
T cell proliferative and anomalous cyto toxic responses in leukaemic patients.  
*British Journal of Haematology.* 47:633. 1981.
9. Souhami RL, Harper PG, Goldstone AH, Tobias JS, Richards JDM, Spiro SG, Geddes DM.  
High dose cyclophosphamide with autologous bone marrow transplantation as initial treatment of small cell bronchogenic carcinoma.  
*Experimental Haematology.* 11:171. 1983.

10. Linch DC, Knott LJ, Thomas R, Harper P, Goldstone AH, Davies EG, Levinsky RJ.  
T cell regeneration after allogeneic and autologous bone marrow transplantation.  
*Experimental Haematology*. 10:133. 1982.
11. Yardumian DA, Bull H, Goldstone AH, Mackie IJ, Machin SJ.  
Zk36374, a stable analogue of prostacyclin can induce platelet hyperaggregability following infusions of short duration and during prolonged infusions.  
*Thrombosis and Haemostasis*. 54:68. 1984.
12. Anderson CC, Martin PJ, Moss FM, Lai A, Richards JDM, Goldstone AH.  
The percentage of large unstained cells (lucs) as measured on the Haemalog-D as an indicator of early regeneration post marrow grafting.  
*British Journal of Haematology*. 58:197. 1984.
13. Philip T, Biron P, Maraninch D, Gastaut JA, Herve P, Flesh Y, Goldstone AH, Souhami RL.  
Role of massive chemotherapy and autologous bone marrow transplantation in non-Hodgkin's malignant lymphoma.  
*Lancet*. 1:391. 1984.
14. Yardumian DA, Mackie IJ, Goldstone AH, Machin SJ.  
The effects of a new prostacyclin analog (zk36374) on platelet function invitro and exvivo.  
*British Journal of Haematology*. 56:674. 1984.
15. Goldstone AH.  
Autologous bone marrow transplantation - forward.  
*Clinics in Haematology*. 15:R 9-R 10. 1985.
16. Goldstone AH, Anderson CC, Souhami RI, Linch DC, Harper PG, Mclellan KA, Jones M, Machin SJ, Jelliffe AM, Cawley JC, Richards JDM.  
Very high dose chemotherapy with ABMT in adult patients with resistant relapsed lymphoma.  
*International Journal of Cell Cloning*. 3:225. 1985.
17. Goldstone AH.  
2nd EBMT survey of ABMT in lymphoma.  
*International Journal of Cell Cloning*. 3:225-226. 1985.
18. Goldstone AH, Anderson CC, Cawley JC, Linch DC, Jones MJ, Franklin JM, Boughton BJ, Richards JDM.  
An update of patients with acute leukaemia treated with intensive chemotherapy and a double autograft protocol, previously presented in November 1983.  
*British Journal of Haematology*. 61:563. 1985.

19. Gribben JG, Goldstone AH, Dones L.  
Central nervous system involvement in patients receiving autologous bone marrow transplantation for non Hodgkin's lymphoma.  
British Journal of Cancer. 56:863. 1987.
20. Armitage RJ, Goldstone AH, Richards JDM, Cawley JC.  
T-cell and B-cell function after autologous bone marrow transplantation (ABMT).  
British Journal of Haematology. 64:821. 1986.
21. Prentice HG, Smyth JF, Ganeshagani K, Wonke B, Bradstock KF, Janossy G, Goldstone AH, Hoffbrand AV. 1980.  
Remission induction with adenosine deaminase inhibitor 2-deoxycoformycin in Thy-lymphoblastic leukaemia.  
Lancet 1980. July 26:2 (8187) 170-2
22. Al-Hadithy H, Addison IE, Goldstone AH, Shaw J, Cawley JC. 1981.  
Defective neutrophil function in low birth weight premature infants.  
J. Clin. Path. 34:366-370
21. Giles FJ, Singer CRJ, Goldstone AH, Tobias JS, Richards JDM.  
Lung toxicity of Melphalan and steroid combination therapy in multiple myeloma.  
British Journal of Cancer. 58:545. 1988.
22. Giles FJ, Newland AC, Goldstone AH.  
Therapy of immune mediated thrombocytopenia post autologous bone marrow transplantation - a pilot study.  
British Journal of Cancer. 58:545. 1988.
23. Giles FJ, Machin SJ, Goldstone AH.  
Alpha-2B interferon as induction therapy in essential thrombocythaemia.  
British Journal of Haematology. 69:108. 1988.
24. Gribben JG, Goldstone AH, Linch DC, Richards JDM, Dones L.  
Autologous bone marrow transplantation (ABMT) in acute leukaemia.  
British Journal of Cancer. 56:871-872. 1987.
25. Gribben JG, Goldstone AH, Dones L, Ernst P.  
Bone marrow transplantation in lymphoblastic lymphoma in remission - autologous versus allogenic.  
British Journal of Cancer. 56:862-863. 1987.
26. McNally T, Kinsey SE, Machin SJ, Weller IVD, Dalton R, Savidge GF, Goldstone AH.  
Investigation of haematological abnormalities occurring with disease progression in HIV infection as assessed by the CDC classification, in male-homosexuals and haemophiliacs.

- British Journal of Haematology. 68:110. 1988.
27. Gribben JG, Goldstone AH, Linch DC, Souhami RL, Vaughanhudson G, Tobias JS.  
Salvage therapy in relapsed Hodgkin's disease by high dose chemotherapy and autologous bone marrow transplantation (ABMT) - outcome and indications. British Journal of Cancer. 56:872. 1987.
28. Juliusson G, Abrahamsen AF, Cavallinstahl E, Goldstone AH, Lister TA, Nissen NI, Robert KH, Singer CRJ, Somers R, Ost A, Gahrton G.  
Management of non-Hodgkin's lymphoma in adults in Scandinavia, United Kingdom and the Netherlands. Report from the European school of oncology intercity meeting at Huddinge Hospital, 3 rd June 1988. Acta Oncologica 28:135-140. 1989.
29. Devereux S, Macmillan A, Gribben J, Patterson K, Goldstone AH, Linch DC.  
Phase-i phase ii studies of rh gm-csf after autologous bone marrow transplantation in Hodgkin's disease. Bone Marrow Transplantation. 3:91. 1988.
30. Devereux S, Goldstone AH, Patterson K, Linch DC.  
The use of recombinant human granulocyte macrophage colony stimulating factor to accelerate recovery of the autologous bone marrow transplantation in man. British Journal of Haematology. 69:103. 1988
31. Devereux S, Costa DC, Gribben J, Spittle MF, Jelliffe AM, Goldstone AH, Linch DC.  
Preliminary studies of recombinant gm-csf in man. British Journal of Cancer. 57:231. 1988.
32. Giles FJ, Goldstone AH.  
Alpha interferon therapy of essential thrombocythemia. British Journal of Cancer. 58:546. 1988.
33. Mcmillan AK, Goldstone AH, Chopra R, Linch DC.  
A comparison of the outcome of ABMT in first remission acute myeloid and lymphoblastic leukaemia in a single centre. Bone Marrow Transplantation. 6:72. 1990.
34. Tobias JS, Giles FJ, Singer CRJ, Richards JDM, Goldstone AH.  
Double half body irradiation for drug resistant multiple myeloma - an effective and well tolerated salvage regimen. British Journal of Cancer 61:182. 1990.
35. Khwaja A, Jones HM, Yong K, Chopra R, Macmillan A, Goldstone AH, Ruthven K, Abramson S, Linch DC. The effects of macrophage colony

- stimulating factor on haematological recovery following autologous bone marrow transplantation.  
Experimental Haematology. 19:560. 1991.
36. Powles RL, Goldstone AH, Stevens R, Dawson A.  
Co-operation between United Kingdom and Soviet-Union.  
British Medical Journal. 302:1468. 1991.
37. Goldstone AH, Burnett AK, Hann I, Stevens RF, Rees J, Wheatley K, Gray R.  
The impact of intensive chemotherapy alone or with additional bone marrow transplantation on remission duration in AML progress report on the MRC 10 trial.  
Experimental Haematology. 19:531. 1991.
38. Williams CD, Goldstone AH, Pearce R, Taghipour G, Green ES, Philip T.  
Non Hodgkin's lymphoma (NHL) with central nervous system involvement - results of autologous bone marrow transplantation from the EBMTG.  
British Journal of Haematology. 84:53. 1992.
39. Goldstone AH, Mcmillan AK.  
Conceptual problems in relation to dose escalation in the first remission of Hodgkin's disease.  
Annals of Oncology 3:S 91-S 93, 1992.
40. Goldstone AH, Martino P.  
Teicoplanin in gram-positive infections - an approach for the nineties.  
British Journal of Haematology. 82:280-281. 1992.
41. Khwaja A, Chopra R, Goldstone AH, Linch DC.  
Acute phase response in patients given RHIL-3 after chemotherapy.  
Lancet 339:1617. 1992.
42. Mcsweeney EN, Giles FJ, Grant IR, Goldstone AH.  
Anti-IFN antibodies in patients with myeloproliferative associated thrombocytosis treated with IFN-alpha.  
British Journal of Haematology. 84:37. 1993.
43. Mcsweeney EN, Chopra R, Goldstone AH.  
Autologous bone marrow transplantation in chronic granulocytic leukaemia - the University College Hospital experience.  
British Journal of Haematology. 84:50. 1993.
44. Mcsweeney EN, Addison IE, Worman CP, Isenberg DA, Goldstone AH.  
Autoantibody induction in patients treated with recombinant alpha-interferon.  
British Journal of Haematology. 84:32. 1993.
45. Mills W, Strang J, Chopra R, Linch DC, Goldstone AH.

- Successful treatment with ambisome of proven aspergillus infection complicating neutropenia.  
British Journal of Haematology. 84:32. 1993.
46. Pollard Y, Jones S, Carter AB, Goldstone AH, Linch DC, Machin SJ. Automated reticulocyte counts with RNA quantification to monitor stem cell transplantation.  
British Journal of Haematology. 84:61. 1993.
47. Tsakona CP, Worman CP, Mcsweeney E, Jewell A, Goldstone AH. Plasma M-CSF levels in AML as a marker of disease activity and response to treatment with alpha-2a interferon.  
British Journal of Haematology. 84:33, 1993.
48. Tsakona CP, Mitsou J, Mcgrouther DA, Crowe R, Goldstone AH, Worman Cd8+ lymphocytes bearing cytoplasmic BLT-specific serine esterase are effectors of rejection of completely mismatched skin allografts in the rat.  
British Journal of Haematology. 84:54. 1993.
49. Williams CD, Pearce R, Taghipour G, Goldstone AH. Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma - a case matched comparison with unpurged cases by the EBMT-lymphoma registry.  
Blood 82:A 444. 1993.
50. Fielding AK, McMillan AK, Chopra R, Tobias JS, Linch DC, Goldstone AH. Feasibility of radiotherapy as consolidation post beam autograft for Hodgkin's disease.  
British Journal of Haematology. 84:53. 1993.
51. Goldstone AH, Mcmillan AK. The place of high dose therapy with haematopoietic stem-cell transplantation in relapsed and refractory Hodgkin's disease.  
Annals of Oncology 4:S 21-S 27. 1993.
52. Goldstone AH, Dicke K. Proceedings of the Portofino symposium on autografting for chronic myeloid leukaemia - status of art - meeting summary.  
Stem Cells 11:131-134. 1993.
53. Jewell AP, Worman CP, Giles FJ, Lydyard PM, Goldstone AH. Cytokine regulation of apoptosis of B-CLI cells invitro.  
Blood 82:A567. 1993.
54. Jones HM, Jones SA, Khwaja A, Watts M, Mills W, Goldstone AH, Linch DC. Critical analysis of the parameters used for monitoring peripheral blood stem cell (PBSC) harvesting.

- British Journal of Haematology. 84:12. 1993.
55. Jones HM, Jones SA, Watts MJ, Mills W, Khwaja A, Goldstone AH, Linch DC.  
The effects of variation of the dose and schedule of G-CSF administration after low dose cyclophosphamide (1.5 g/m<sup>2</sup>) on both neutrophil and peripheral blood haematopoietic progenitor-cell levels.  
Blood 82:A233. 1993.
56. Khwaja A, Mills W, Leveridge K, Goldstone AH, Linch DC.  
Efficacy of delayed granulocyte colony stimulating factor (G-CSF) after autologous bone marrow transplantation (ABMT).  
British Journal of Haematology. 84:12. 1993.
57. Khwaja A, Goldstone AH, Linch DC,  
Patients with delayed neutrophil recovery after autologous bone marrow transplantation (ABMT) for lymphoma not receiving haematopoietic growth factors do not have increased mortality from inception.  
Blood 82:A 424. 1993.
58. McSweeney EN, Mills W, Chopra R, Mcmillan AK, Tobias JS, Goldstone AH.  
Autologous bone marrow transplantation in multiple myeloma. The University College Hospital London experience.  
British Journal of Haematology. 84:14. 1993.
59. Chatterjee R, Mills W, McGarrigle HHG, Goldstone AH.  
Abnormal growth hormone (GH) pulsatility in patients with haematological malignancies presenting with premature ovarian failure following high dose ablative treatment and bone marrow transplantation.  
British Journal of Haematology. 84:51. 1993.
60. Chatterjee R, Mills W, Katz M, McGorrigle HHG, Linch DC, Goldstone AH.  
Evaluation of short and long term effects of TBI versus beam on hypothalamic pituitary gonadal (HPG) axis in patients with haematological malignancies.  
British Journal of Haematology. 84:52. 1993.
61. Liberti G, Pearce R, Taghipour G, Majolino I, Goldstone AH.  
Comparison on peripheral blood stem cell and autologous bone marrow transplantation for lymphoma patients - a case controlled analysis of the EBMT registry data.  
Annals of Oncology 5:S 151-S 153, 1994.
62. Schmitz N, Linch DC, Dreger P, Boogaerts MA, Goldstone AH, Ferrant A, Demuyneck HMS, Link H, Zander A, Matcham J, Borkett KM, Schwab G.  
A randomised phase-iii study of filgrastim mobilised peripheral blood progenitor cell transplantation (PBPCT) in comparison with autologous bone

marrow transplantation (ABMT) in patients with Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL).  
Blood 84:A 204. 1994.

63. Schouten HC, Colombat P, Verdonck LF, Gorin NC, Bjorkstrand B, Taghipour G, Goldstone AH.  
Autologous bone marrow transplantation for low grade non-Hodgkin's lymphoma - the European bone marrow transplant group experience.  
Annals of Oncology. 5:S, 147-S 149, 1994.

64. Sweetenham JW, Proctor SJ, Blaise D, deLaurenzi A, Pearce R, Taghipour G, Goldstone AH.  
High dose therapy and autologous bone marrow transplantation in first complete remission for adult patients with high grade non-Hodgkin's lymphoma - the EBMT experience.  
Annals of Oncology 5:S 155-S 159. 1994.

65. Burnett AK, Goldstone AH, Stevens RF, Hann IM, Rees JK, Wheatley K, Gray RG.  
The role of BMT in addition to intensive chemotherapy in AML in first CR - results of the MRC AML 10 trial.  
Blood 84:A 252. 1994.

66. Chalmers EA, Franklin IM, Kelsey S, Clarke R, Spoul AM, Goldstone AH, Hepplestone A, Watson W, Sharp S, Tansey P.  
Mobilisation of ph-negative peripheral blood stem cells in CML with idarubicin and cytarabine.  
Bone Marrow Transplantation. 14:S 38-S 41. 1994.

67. Chalmers EA, Franklin IM, Kelsey S, Clarke R, Sproul AM, Goldstone AH, Hepplestone A, Watson W, Sharp S, Tansey P.  
Mobilisation of ph-negative progenitors into peripheral blood in chronic myeloid leukaemia (CML) using idarubicin and cytarabine.  
Blood 84:A 400. 1994.

68. Fielding AK, Philip T, Carella A, Gorin NC, Colombat P, Pearce RM, Goldstone AH.  
Autologous bone marrow transplantation for lymphomas - a 15 year European bone marrow transplant registry (EBMT) experience of 3325 patients.  
Blood 84:A 536, 1994.

69. Goldstone AH, O'Driscoll A,  
Early ambisome in febrile neutropenia in patients with haematological disorders.  
Bone Marrow Transplantation. 14:S 15-S 17. 1994.

70. Schmitz N, Hasenclever D, Brosteanu O, Carella A, Colombat P, Proctor S, Legros M, Bradley S, Pearce R, Diehl V, Goldstone AH.

Early high dose therapy to consolidate patients with high risk Hodgkin's disease in first complete remission - results of EBMT/GHSG matched pair analysis.  
Blood 86:1742. 1995.

71. Sweetenham JW, Pearce R, Taghipour G, Goldstone AH.  
Adult burkitts and burkitt like non-Hodgkin's lymphoma (NHL) - favourable outcome for patients undergoing high dose therapy and autologous stem cell transplantation (ASCT) in first remission or chemosensitive relapse - results from the EBMT.  
Blood 86:832. 1995.

72. Vandenberghe E, Pearce R, Taghipour G, Goldstone AH.  
2 auto transplants for lymphoma - acceptable toxicity (18-percent) of the second transplant and significant survival length in some patients - data from the EBMT lymphoma registry.  
Blood 86:3871. 1995.

73. Watts MJ, Sullivan AM, Jamieson E, Fielding A, Pearce RM, Goldstone AH, Linch DC.  
Adequacy of stem cell collection in relapsed and resistant lymphomas mobilised with cyclophosphamide 1.5 g/m<sup>2</sup> and g-CSF.  
Blood 86:1621. 1995.

74. Williams CD, Fielding AK, Pearce RM, Watts MJ, Tobias JS, Linch DC, Goldstone AH.  
Peripheral blood stem cell transplantation (PBSCT) for multiple-myeloma - a single centre experience of 23 patients.  
Blood 86:3883. 1995.

75. Bjorkstrand B, Ljungman P, Brandt L, Brunet S, Carlson K, Cavo M, Fassas A, Ferrant A, Goldstone AH, deLaurezi A, Prentice HG, Remes K, Samson D, Verdonck LF, Gahrton G.  
Autologous stem cell transplantation (ASCT) in multiple myeloma - a study of the European BMT registry.  
Blood 84:A 535. 1994.

76. Burnett AK, Goldstone AH, Stevens RF, Hann I, Rees J, Wheatley K.  
Risk characteristics of disease in AML dictate response to treatment in AML in CR-1.  
Experimental Haematology. 23:861.1995.

77. Burnett AK, Goldstone AH, Stevens RF, Hann I, Rees J, Wheatley K.  
Evaluation of bone marrow transplantation for acute myeloid leukaemia after intensive chemotherapy.  
Experimental haematology. 23:843. 1995.

78. Cahn JY, Labopin M, Mandelli F, Goldstone AH, Eberhardt K, Reiffers J, Ferrant A, Franklin I, Herve P, Gratwohl A, Gorin NC.

Autologous bone marrow transplantation for first remission acute myeloblastic leukaemia in patients older than 50 years - a retrospective analysis of the European bone marrow transplant group.  
*Blood* 85:575-579. 1995.

79. Carella AM, Goldstone AH.  
2nd International meeting on high-risk Hodgkin's disease, Hotel Plaza-Luccesi, Florence Italy, May 6-7th 1994. preface.  
*Leukaemia & Lymphoma*. 15:1. 1995.

80. Chalmers EA, Franklin IM, Kelsey SM, Newland AC, Clark RE, Sproul AM, Crotty G, McCann SR, Fielding A, Goldstone AH, Hepplestone A, Watson W, Sharp RA, Tansey P.  
Duration of chronic phase correlates with the ability to mobilise Philadelphia negative peripheral blood stem cells in chronic myeloid leukaemia.  
*Experimental Haematology*. 23:791, 1995.

81. Goldstone AH, Wheatley K, Burnett AK, Gray R, Rees JKH, Hann I, Stevens RF.  
Relapsing patients with MRC AML 10 trial - no evidence yet of benefit from rainy day harvest and autotransplant for patients in 2nd remission.  
*Blood* 86:359. 1995.

82. Kolb HJ, Duell T, Socie G, Vanlint MT, Carreras E, Tichelli A, Ljungman P, Jacobsen N, Apperley JF, Hertenstein B, Weiss M, Nekolla E, Goldstone AH.  
New malignancies in patients surviving more than 5 years after marrow transplantation.  
*Blood* 86: 1825. 1995.

83. Linch DC, Milligan DW, Winfield DA, Kelsey S, Johnson S, Littlewood T, Smith G, Hutching MR, Goldstone AH, Fielding A, Williams M, Hartley S, Long SG.  
G-CSF significantly accelerates neutrophil recovery after peripheral blood stem cell transplantation (PBSCT) in lymphoma patients and shortens the time in hospital - preliminary results of a randomised BNLI trial.  
*Blood* 86:873. 1995.

84. Fielding AK, Pearce RM, Goldstone AH.  
Bone marrow transplantation versus chemotherapy in non-Hodgkin's lymphoma.  
*New England Journal of Medicine*. 333:729. 1995.

85. Watson W, Wheatley K, Burnett AK, Goldstone AH, Rees JK, Gray RG.  
The impact of allogeneic (allo-BMT) and autologous (ABMT) bone marrow transplant in first complete remission (CR-1) on quality of life(ql) of patients with acute myeloid leukaemia (AML) entered into the MRC AML 10 trial.  
*British Journal of Haematology*. 93:559. 1996.

86. Watts MJ, Sullivan AM, Leverett D, Macmillan AK, Patterson K, Devereux S, Goldstone AH, Linch DC.  
Evaluation of the eshap regimen followed G-CSF for PBSC mobilisation - a matched pairs analysis compared to low dose cyclophosphamide 1.5g/m<sup>2</sup> plus G-CSF.  
British Journal of Haematology. 93:167. 1996.
87. Watts MJ, Sullivan AM, Goldstone AH, Linch DC.  
Feasibility of clinical scale cd34+ cell purification of peripheral blood stem cell harvests - experience of 40 immunoaffinity column procedures.  
British Journal of Haematology. 93:46. 1996.
88. Watts MJ, Leverett D, Sullivan AM, Peniket AJ, Perry AR, Macmillan A, Goldstone AH, Linch DC.  
A comparison of eshap+g-CSF vs cyclophosphamide 1.5g/m<sup>2</sup>+g-CSF for PBSC mobilisation in pretreated lymphoma patients - a matched pair analysis.  
Blood 88:1571. 1996.
89. Wheatley K, Burnett AK, Goldstone AH, Hann M, Stevens RF, Rees JKH, Gray RG.  
Factors relating to the achievement of complete remission (CR) in younger patients with acute myeloid leukaemia (AML) in the United Kingdom Medical Research Council (MRC) AML-10 trial.  
Blood 88:843. 1996.
90. Williams CD, Watts MJ, Sullivan AM, Leverett D, Linch DC, Goldstone AH.  
Successful cd34+ cell mobilisation is predictive of a survival advantage to patients with myeloma undergoing peripheral blood stem cell transplantation.  
British Journal of Haematology. 93:302. 1996.
91. Williams CD, Taghipour G, Lister TA, Blystaad AM, Coiffier B, Goldstone AH.  
Chemosensitive transformed follicular non-Hodgkin's lymphoma (NHL) is a firm indication for high dose therapy and autologous stem cell transplantation - a study from the EBMT registry.  
Blood 88:2727. 1996.
92. Burnett AK, Goldstone AH, Stevens R, Hann I, Rees JK, Wheatley K.  
Biological characteristics of disease determine the outcome of allogeneic or autologous BMT in AML CRL.  
Blood 86:2452. 1995.
93. Nokes TJC, Johnson S, Grubb H, Shirley J, Vandepette J, Reid C, Simpson CN, Dodd NJ, Harvey D, Goldstone AH.  
The use of FLAG in patients with haematological malignancies, a multicentre experience.  
British Journal of Haematology. 93:254. 1996

94. Sullivan AM, Watts MJ, Leverett D, Williams CD, Goldstone AH, Linch DC.  
Failure to mobilise peripheral blood stem cells reflect poor quality bone marrow.  
British Journal of Haematology. 93:147. 1996
95. Sweetenham JW, Taghipour G, Linch DC, Goldstone AH.  
30 percent of adult patients with primary refractory Hodgkin's disease (HD) are progression free at 5 years after high dose therapy (HDT) and autologous stem cell transplantation (ASCT) - data from 290 patients reported to the EBMT.  
Blood 88:1932. 1996.
96. Sweetenham JW, Taghipour G, Linch DC, Goldstone AH.  
High dose therapy (HDT) and autologous stem cell transplantation (ASCT) for adults with Hodgkin's disease (HD) in first relapse after chemotherapy - conventional dose salvage therapy prior to ASCT has no effect on outcome - results from the EBMT. Blood 88:1933. 1996.
97. Sweetenham JW, Santini G, Simnett S, Gibson D, Guelfi M, Bruzzi P, Machin D, Goldstone AH.  
Conventional dose versus high dose postremission therapy for adults with lymphoblastic lymphoma - a progress report on the EBMT/UKLG trial and a preliminary analysis of prognostic factors.  
Blood 88:484. 1996.
98. Vandenbergh E, Taghipour G, Goldstone AH.  
The real lymphoma classification system predicts response to high dose therapy and stem cell rescue - a study from the European blood and marrow (EBMT) group.  
Blood 88:2726. 1996.
99. Burnett AK, Goldstone AH, Wheatley K.  
Improved outcome of patients with APL following the introduction of all-trans retinoid acid (ATRA) to an intensive chemotherapy schedule.  
British Journal of Haematology. 83:819 1996
100. Chatterjee R, Mills W, Katz M, McGarrigle, HH, Goldstone AH.  
Androgen replacement therapy in patients presenting with premature andropause with haematological malignancy treated by myeloablative chemoradiotherapy.  
British Journal of Haematology. 93:175. 1996.
101. Goldstone AH, Burnett AK, Wheatley K, Gray RG.  
Identification of good risk elderly patients with acute myeloid leukaemia (AML) who benefit from intensive therapy and extremely poor risk ones who do not - prognostic factor - analysis of the MRC AML 11 trial.  
Blood 88:1154. 1996.

102. Gratwohl A, Hermans J, Schmitz N, Gorin NC, Apperley J, Goldstone AH, Rosti G, Gahrton G, Bacigalupo A.  
Bone marrow stem cell transplants in Europe.  
Experimental Haematology 24:656. 1996.
103. Harrison CN, Hudson GV, Perry A, Anderson L, Macmillan A, Devereux S, Goldstone AH, Linch DC.  
Beam and ABMT:PBSCT may reduce the risk of secondary leukaemia in Hodgkin's disease - a case control analysis with the BNLI database.  
Blood 88:1036. 1996.
104. Langabeer SE, Walker H, Wheatley K, Burnett AK, Goldstone AH, Linch DC.  
Frequency of CFBF/MYH11 fusion transcripts in acute myelomonocytic leukaemia (AML M4).  
British Journal of Haematology. 93:235. 1996.
105. Peniket AJ, deElvira MCR, Taghipour G, deWitte T, Tazelaar PJ, Carella A, Vernant JP, Schaefer UW, Cleeven M, Boogaerts MA, Gluckman E, Goldstone AH.  
Allogenic transplantation for lymphoma produces a lower relapse rate than autologous transplantation but survival is worse because of higher treatment related mortality - a report of 764 cases from the EBMT lymphoma registry.  
Blood 90:1121. 1997.
106. Peniket AJ, Perry AR, Leverett D, Watts M, Sullivan A, Linch DC, Goldstone AH.  
Which PBPC patients may benefit from accelerated platelet recovery? Factors affecting hospital discharge in 152 consecutive patients, the relevance of cd34 dose and the potential implications of megakaryocyte growth factor.  
Blood 90:1701. 1997.
107. Peniket AJ, Howard MR, Preiser W, Perry AR, Kottaridis PD, McKeag N, Brink NS, Mackinnon S, Goldstone AH.  
Pre-emptive anti-CMV therapy during allogeneic bone marrow transplantation based upon blood PCR surveillance produces molecular evidence of effective viral clearance with absence of clinically detectable disease.  
Blood 90:2423. 1997.
108. Peniket AJ, Kottaridis PD, Perry AR, DeElvira MCR, Devereux S, Macmillan A, Goldstone AH, Linch DC.  
Outcome of bean autotransplantation in patients with Hodgkin's disease progressing on first line therapy is the same as in patients transplanted in first partial remission.  
Blood 90:497. 1997.
109. Sweetenham JW, Bierman P, Taghipour G, Gratwohl A, Hagenbeek A, Greinix H, Schaefer UW, Goldstone AH.

Two thirds of adult patients (PTS) with lymphoma achieve long term survival after syngeneic bone marrow transplantation (BMT) - results from the EBMT. *Blood* 90:4512. 1997

110. Watts MJ, Sullivan AM, Leverett D, Peniket AJ, Williams CD, Devereux S, Goldstone AH, Linch DC.  
Backup bone marrow is frequently ineffective in patients with poor peripheral blood progenitor cell mobilisation.  
*Blood* 90:938. 1997.

111. Bjorkstrand B, Ljungman P, Svensson H, Hermans I, Alegre A, Apperley I, Blade I, Carlson K, Cavo M, Ferrant A, Goldstone AH, deLaurenzi A, Majolino I, Marcus R, Prentice HG, Remes K, Samson D, Sureda A, Verdonck LF, Volin L, Gahrton G.  
Autologous stem cell transplantation is associated with better survival than allogeneic BMT in multiple myeloma - results of a retrospective case matched study in 378.  
*Experimental Haematology*. 24:657. 1998.

112. Burnett AK, Goldstone AH, Stevens R, Hann IM, Gray R, Rees J.  
Allo and auto BMT reduce relapse risk in AML in CR-1 but do not significantly improve overall survival - results of the MRC AML 10 trial.  
*British Journal of Haematology*. 93:1184. 1998.

113. Belkacemi Y, Labopin M, Vernant JP, Prentice HG, Tichelli A, deWitte T, Boogaerts MA, ERnst P, DellaVolpe A, Goldstone AH, Jouet JP, Verdonck LF, Rio B, Locasciulli A, Ozsahin M, Gorin NC.  
Cataracts following bone marrow transplantation (BMT) conditioned with total body irradiation (TBI) for acute leukaemia (AL) in complete remission (CR): a study of the European Group for Blood and Marrow Transplantation.  
*International Journal of Radiation Oncology Biology Physics*. 39:175. 1998.

114. Bjorkstrand B, Svensson K, Ljungman P, Apperley J, Goldschmidt H, Remes K, Alegre A, Marcus R, Carlson K, Coser P, Sureda A, Barbui T, Goldstone AH, Blade J Volin L, Boogaerts M, Lenhoff S, Majolino I, Samson D, deLaurenzi A, Caballero D, Gahrton, G. 2522 autotransplants in multiple myeloma - a registry study from the European Group for Blood and Marrow Transplantation (EBMT).  
*Blood* 90:1862. 1998.

115. Burnett AK, Wheatley K, Langabeer S, Walker H, Linch D, Goldstone AH, Hann I, Stevens RF.  
Outcome of acute myeloid leukaemias affecting core binding factor subunits: the UK MRC experience.  
*Blood* 90:1737. 1997.

116. Burnett AK, Goldstone AH, Gray RG, Wheatley K.  
All transretinoic acid given concurrently with induction chemotherapy improves the outcome of APL: results of the UK MRC ara trial.

Blood 90:1474. 1997.

117. Fanin R, Silvestri F, deElivra MCR, Tahipour G, Sperotto A, Goldstone AH.

Autologous stem cell transplantation for T and null-cell types CD-30 positive anaplastic large cell lymphoma: preliminary analysis of 65 cases reported to the EBMT.

Blood 90:1021. 1997.

118. Goldstone AH, Burnett AK, Milligan DW, Prentice AG, Wheatley K. Lack of benefit of G-CSF on complete remission and possible increased relapse risk in AML: an MRC study of 800 patients.

Blood 90:2595. 1997.

119. Kottaridis PD, Peniket AJ, Perry AR, Harrison CN, deElvira MCR, Macmillan A, Devereux S, Linch DC, Goldstone AH.

The length of the first complete remission (1-6 months; 7-12 months; 12 months) does not predict outcome following beam and autotransplantation for Hodgkin's disease in first relapse.

Blood 90:496. 1998.

120. Murphy MF, Murphy W, Wheatley K, Goldstone AH.

Survey of the use of platelet transfusions in centres participating MRC leukaemia trials.

British Journal of Haematology. 102(3):875-6. 1998 August.

121. Watts MJ, Sullivan AM, Ings SJ, Barlow M, Devereux S, Goldstone AH, Linch DC.

Storage of PBSC at -80 degrees.

Bone Marrow Transplantation. 21(1):111-2. 1998 January.

122. Kottaridis PD, Milligan DW, Chopra R, Chakraverty R, Chakrabarti S, Robinson S, Peggs K, Pettengell R, Marsh J, Mahendra P, Schey S, Morgan G, Williams C, Hale G, Waldmann H, Linch DC, Devereux S, Goldstone AH, Mackinnon S.

In vivo Campath-1H prevents graft versus host disease following non myeloablative stem cell transplantation.

Blood 2000;96:2419-25

134 Sweetenham JW, Santini G, Qian W, Guelfi M, Schmitz N, Simnett S, Nagler A, Holte H, Kvaloy S, Bruzzi P, Goldstone AH. High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group. J Clin Oncol. 2001 Jun 1;19(11):2927-36.

135 Williams CD, Harrison CN, Lister TA, Norton AJ, Blystad AK, Coiffier B, Taghipour G, Schmitz N, Goldstone AH; European Bone Marrow

Transplant Lymphoma Working Party. High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. *J Clin Oncol.* 2001 Feb 1;19(3):727-35.

123. Peggs K, Morris E, Kottaridis PD, Geary J, Goldstone AH, Linch DC, Mackinnon S.  
Outcome of major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation may be influenced by conditioning regimen.  
*Blood* 2002;99:4642-3

124. Branson K, Chopra R, Kottaridis PD, McQuaker G, Parker A, Schey, Chakraverty R, Craddock C, Milligan D, Pettengell R, Marsh J, Linch DC, Goldstone AH, Williams C, Mackinnon SJ.  
Transplantation after failure of autologous transplant in patients with lymphoproliferative malignancies.  
*Clin Oncol*; in press.

125. Perez-Simon JS, Pangiotis D, Kottaridis P, Martino R, Craddock C, Caballero D, Chopra R, Garcia-Conde J, Milligan DW, Schey S, Urbano-Ispiu A, Parker A, Sureda A, Hunter A, Sierra J, Goldstone AH, Linch DC, San Miguel JF, Mackinnon S.  
Non-myeloablative transplants with or without CAMPATH-1H: Comparison between two prospective studies in patients with lymphoproliferative disorders.  
*Blood*; in press.

126. Chakrabarti S, Mackinnon S, Chopra R, Kottaridis PD, Peggs K, O'Gorman P, Chakraverty R, Marshall T, Osman H, Mahendra P, Craddock C, Waldmann H, Hale G, Fegan CD, Yong K, Goldstone AH, Linch DC, Milligan DW.  
High incidence of early and late CMV infection and slow reconstitution of T-cell subsets after allogeneic transplants with nonmyeloablative conditioning using Campath (Anti-CD52 antibody).  
*Blood*:2002;99:4357-63.

127. Chakraverty R, Peggs K, Chopra R, Milligan DW, Kottaridis PD, Verfuert S, Geary J, Branson K, Chakrabarti S, Mahendra P, Craddock C, Parkre A, Hunter A, Hale G, Waldmann H, Williams CD, Yong K, Linch DC, Goldstone AH, Mackinnon S.  
Limiting transplant related mortality following unrelated donor stem cell transplant by using a non-myeloablative conditioning regimen.  
*Blood*:2002;99:1071-8.

132 Robinson SP, Goldstone AH, Mackinnon S, Carella A, Russell N, de Elvira CR, Taghipour G, Schmitz N; Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Chemo-resistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the

Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. *Blood*. 2002 Dec 15;100(13):4310-6.

133 Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, Boissevain F, Zschaber R, Muller P, Kirchner H, Lohri A, Decker S, Koch B, Hasenclever D, Goldstone AH, Diehl V; German Hodgkin's Lymphoma Study Group; Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. *Lancet*. 2002 Jun 15;359(9323):2065-71.

139 Sweetenham JW, Taghipour G, Milligan D, Blystad AK, Caballero D, Fassas A, Goldstone AH. High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. *Bone Marrow Transplant*. 1997 Nov;20(9):745-52.

140 Ladenstein R, Pearce R, Hartmann O, Patte C, Goldstone T, Philip T. High-dose chemotherapy with autologous bone marrow rescue in children with poor-risk Burkitt's lymphoma: a report from the European Lymphoma Bone Marrow Transplantation Registry. *Blood*. 1997 Oct 15;90(8):2921-30.

141 Vandenberghe E, Pearce R, Taghipour G, Fouillard L, Goldstone AH. Role of a second transplant in the management of poor-prognosis lymphomas: a report from the European Blood and Bone Marrow Registry. *J Clin Oncol*. 1997 Apr;15(4):1595-600.

142 Majolino I, Pearce R, Taghipour G, Goldstone AH. Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. *J Clin Oncol*. 1997 Feb;15(2):509-17.

143 Sweetenham JW, Pearce R, Taghipour G, Blaise D, Gisselbrecht C, Goldstone AH. Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma--outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation. *J Clin Oncol*. 1996 Sep;14(9):2465-72.

144 Williams CD, Goldstone AH, Pearce RM, Philip T, Hartmann O, Colombat P, Santini G, Foulard L, Gorin NC. Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry. *J Clin Oncol*. 1996 Sep;14(9):2454-64.

- 145 Milpied N, Fielding AK, Pearce RM, Ernst P, Goldstone AH. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation. *J Clin Oncol.* 1996 Apr;14(4):1291-6.
- 146 Bradley SJ, Pearce R, Taghipour G, Vaughan-Hudson B, Goldstone AH. First remission autologous bone marrow transplantation for Hodgkin's disease-preliminary EBMT data. *Leuk Lymphoma.* 1995;15 Suppl 1:51-3.
- 147 Sweetenham JW, Pearce R, Philip T, Proctor SJ, Mandelli F, Colombat P, Goldstone AH. High-dose therapy and autologous bone marrow transplantation for intermediate and high grade non-Hodgkin's lymphoma in patients aged 55 years and over: results from the European Group for Bone Marrow Transplantation. The EBMT Lymphoma Working Party. *Bone Marrow Transplant.* 1994 Dec;14(6):981-7.
- 148 Williams CD, Pearce R, Taghipour G, Green ES, Philip T, Goldstone AH. Autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma and CNS involvement: those transplanted with active CNS disease have a poor outcome - a report by the European Bone Marrow Transplant Lymphoma Registry. *J Clin Oncol.* 1994 Nov;12(11):2415
- 149 Sweetenham JW, Liberti G, Pearce R, Taghipour G, Santini G, Goldstone AH. High-dose therapy and autologous bone marrow transplantation for adult patients with lymphoblastic lymphoma: results of the European Group for Bone Marrow Transplantation. *J Clin Oncol.* 1994 Jul;12(7):1358-65.
- 150 Schouten HC, Colombat P, Verdonck LF, Gorin NC, Bjorkstrand B, Taghipour G, Goldstone AH. Autologous bone marrow transplantation for low-grade non-Hodgkin's lymphoma: the European Bone Marrow Transplant Group experience. EBMT Working Party for Lymphoma. *Ann Oncol.* 1994;5 Suppl 2:147-9.
- 151 Liberti G, Pearce R, Taghipour G, Majolino I, Goldstone AH. Comparison of peripheral blood stem-cell and autologous bone marrow transplantation for lymphoma patients: a case-controlled analysis of the EBMT Registry data. Lymphoma Working Party of the EBMT. *Ann Oncol.* 1994;5 Suppl 2:151-3.
- 152 Sweetenham JW, Proctor SJ, Blaise D, De Laurenzi A, Pearce R, Taghipour G, Goldstone AH, Laurenzi A [corrected to De Laurenzi A. High-dose therapy and autologous bone marrow transplantation in first complete remission for adult patients with high-grade non-Hodgkin's lymphoma: the EBMT experience. Lymphoma Working Party of the European Group for Bone Marrow Transplantation. *Ann Oncol.* 1994;5 Suppl 2:155-9. Erratum in: *Ann Oncol.* 1994 May;5(5):475.
- 153 Williams CD, Goldstone AH, Pearce R, Green S, Armitage JO, Carella

A, Meloni G. Autologous bone marrow transplantation for pediatric Hodgkin's disease: a case-matched comparison with adult patients by the European Bone Marrow Transplant Group Lymphoma Registry. *J Clin Oncol.* 1993 Nov;11(11):2243-9.

154 Chopra R, Goldstone AH, Pearce R, Philip T, Petersen F, Appelbaum F, De Vol E, Ernst P. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data. *J Clin Oncol.* 1992 Nov;10(11):1690-5.

155 Goldstone AH, Gribben JG. EBMT experience of autologous bone marrow transplantation in lymphoma. *Folia Haematol Int Mag Klin Morphol Blutforsch.* 1989;116(3-4):505-8

136 Sweetenham JW, Carella AM, Taghipour G, Cunningham D, Marcus R, Della Volpe A, Linch DC, Schmitz N, Goldstone AH. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party. *J Clin Oncol.* 1999 Oct;17(10):3101-9.

137 Milligan DW, Ruiz De Elvira MC, Kolb HJ, Goldstone AH, Meloni G, Rohatiner AZ, Colombat P, Schmitz N. Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation. *Br J Haematol.* 1999 Sep;106(4):1020-6.

138 Fanin R, Ruiz de Elvira MC, Sperotto A, Baccarani M, Goldstone A. Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT). *Bone Marrow Transplant.* 1999 Mar;23(5):437-42.

128 Federico M;Bellei M;Brice P;Brugiatelli M;Nagler A;Gisselbrecht C;Moretti L;Colombat P;Luminari S;Fabbiano F;Di Renzo N;Goldstone A;Carella AM. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. *J Clin Oncol.* 2003; 21:2320-2325

129 Bierman PJ, Sweetenham JW, Loberiza Jr FR, Taghipour G, Lazarus HM, Rizzo JD, Schmitz N, Besien Kv K, Vose JM, Horowitz M, Goldstone A. Syngeneic Hematopoietic Stem-Cell Transplantation for Non-Hodgkin's Lymphoma: A Comparison With Allogeneic and Autologous Transplantation: The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. *J Clin Oncol.* 2003; 21: 3744-3753

130 Peniket AJ, Ruiz de Elvira MC, Taghipour G, Cordonnier C, Gluckman E, de Witte T, Santini G, Blaise D, Greinix H, Ferrant A, Cornelissen J, Schmitz N, Goldstone AH; European Bone Marrow Transplantation (EBMT) Lymphoma Registry. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. *Bone Marrow Transplant.* 2003 Apr;31(8):667-78.

131 Vandenberghe E, Ruiz de Elvira C, Loberiza FR, Conde E, Lopez-Guillermo A, Gisselbrecht C, Guilhot F, Vose JM, van Biesen K, Rizzo JD, Weisenburger DD, Isaacson P, Horowitz MM, Goldstone AH, Lazarus HM, Schmitz N. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. *Br J Haematol.* 2003 Mar;120(5):793-800.

#### **D. REVIEWS**

1. Linch DC, Goldstone AH. 1984.  
Autologous Bone Marrow Transplantation.  
*British Journal of Haematology* 58: 1-7.
2. Linch DC, Goldstone AH. 1987.  
ABMT in Leukaemia. *Bone Marrow Transplantation.*
3. Shaw KM, Wilkinson L, Goldstone AH, McLeod A, Harper PG, Greenbaum R, Bloom A. 1979.  
Experience with glyclazide in newly diagnosed maturity onset diabetes.  
*Royal Society of Medicine, Int. Cong & Symp. Series No 20: 128-135.*
4. Parry ES, Thomas MJG, Marcus RE, Goldstone AH, Huehns ER.  
Characterisation and transfusion of young erythrocytes.  
*British Journal of Haematology.* 50:701. 1982.
5. Goldstone AH, Dones LD.  
Autologous bone marrow transplantation for lymphoma in Europe.  
*Experimental Haematology.* 13:20-21. 1985.
6. Anderson CC, Linch DC, Goldstone AH.  
Double autografting - a potential curative regimen for acute leukaemia.  
*Leukaemia Research.* 10:113. 1986.
7. Goldstone AH.  
EBMT of autologous bone marrow transplantation in Hodgkin disease and non-Hodgkin's lymphoma.  
*Experimental Haematology.* 14:561. 1986.
8. Goldstone AH, Singer CRJ, Gribben JG, Jarret M.

- 5th report of EBMTG experience of ABMT in malignant lymphoma.  
Bone Marrow Transplantation. 3:33-36. 1988.
9. Goldstone AH, Khwaja A.  
The role of haematopoietic growth factors in bone marrow transplantation.  
Leukaemia Research. 14:721-729. 1990.
10. Vyas P, Goldstone AH.  
Bone marrow transplantation.  
Practitioner 234:732-734. 1990
11. Khwaja A, Goldstone AH,  
Haematopoietic growth factors.  
British Medical Journal 302:1164-1165. 1991.
12. Mcmillan AK, Goldstone AH.  
Autologous bone marrow transplantation for non-Hodgkin's lymphoma.  
European Journal of Haematology. 46:129-135. 1991.
13. Mcmillan A, Chopra R, Pearce R, Goldstone AH, Linch DC.  
Treatment of Hodgkin's lymphoma.  
British Medical Journal. 305-367. 1992.
14. Chopra R, Goldstone AH.  
Bone marrow transplantation for lymphoblastic (LBL) lymphoma in adults.  
Experimental Haematology. 19:460. 1991.
15. Chopra R, Goldstone AH.  
Autologous bone marrow transplantation symposium September 1991 -  
introduction.  
Leukaemia and Lymphoma 7:73-77. 1992.
16. Goldstone AH, Diehl V.  
Non Hodgkins lymphoma-ii.  
Bone Marrow Transplantation. 12:S 70-S 72. 1993.
17. Linch DC, Fine LG, Fielding A, Machin SJ, Goldstone AH, Solomon E,  
Gann A.  
Acute promyelocytic leukaemia.  
Lancet 344:1615-1618. 1994.
18. Goldstone AH.  
Significance of high dose therapy in the treatment of high grade malignant  
non-Hodgkin's lymphoma.  
Onkologie 18:78-79. 1995.
19. Vandenberghe EA, Goldstone AH.  
Autologous stem cell transplants in lymphomas.  
Annals of Medicine. 28:137-143. 1996.

20. Chatterjee R, Goldstone AH.  
Gonadal damage and effects on fertility in adult patients with haematological malignancy undergoing stem cell transplantation.  
Bone Marrow Transplantation. 17:5-11. 1996.
21. Liesner R, Goldstone AH.  
Treatment of childhood and adult acute lymphoblastic leukaemia.  
Journal of Internal Medicine. 242:29-36. 1997.
22. Liesner RJ, Goldstone AH.  
ABC of clinical haematology - the acute leukaemias.  
British Medical Journal. 314:733-736. 1997.
23. Goldstone AH.  
The case for and against high-dose therapy with stem cell rescue for early poor prognosis Hodgkin's disease in first remission.  
Ann Oncol. 1998;9 Suppl 5:S83-5.
24. Perry AR, Goldstone AH  
High dose therapy for diffuse large cell lymphoma in first remission.  
Ann. Oncol.1998;9 Suppl. 1 : S9-14
25. Laurence AD, Goldstone AH.  
High dose therapy with haematopoietic transplantation for Hodgkin's lymphoma.  
Semin Haematol. 1999 July;36(3): 303-12.
26. Linch DC, Goldstone AH.  
High-dose therapy for Hodgkin's disease.  
British Journal Haematology. 1999 Dec; 107(4): 685-90.